Publicaciones

 

  • P Malfertheiner, F Megraud, CA O’Morain, JP Gisbert, EJ Kuipers, AT Axon, et al. Management of Helicobacter pylori Infection Maastricht V/ Florence Consensus Report. Gut 2017; 66: 6-30. Artícle.
  • C Fallone, JP Gisbert, N Chiba, S Veldhuyzen Van Zanten, L Fischbach, RH Hunt, N Jones, C Render, GI Leontiadis, P Moayyedi, JK Marshall. Reply to Letters 16-00940 and 16-00927. Gastroenterology 2017; 152: 303-304. Letter.
  • MJ Casanova, M. Chaparro, V. García-Sánchez, O. Nantes, E. Leo, M. Rojas-Feria, A. Jauregui-Amezaga, S. García-López, JM Huguet, F. Arguelles, M. Aicart, I. Marín, M. Gómez-García, F. Muñoz, M. Esteve, L. Bujanda, X. Cortés, J.Tosca, JR. Pineda, E. Domènech, E. García-Planella, J. Guardiola, I. Pérez-Martínez, C. Muñoz, Y. González-Lama, J. Hinojosa, JM Vázquez, MP. Martinez-Montiel, GE. Rodríguez, R. Pajares, MF García-Sepulcre, A. Hernández-Martínez, JL. Pérez-Calle, B. Beltrán, D. Busquets, L. Ramos, F. Bermejo, J. Barrio, M. Barreiro-de Acosta, O. Roncedo, X. Calvet, D. Hervías, F. Gomollón, M. Domínguez, G. Alcaín, B. Sicilia, C. Dueñas, A. Gutiérrez, R. Lorente-Poyatos, M. Montoro, S. Khorrami, C. Muñoz, C. Taxonera, A. Rodríguez-Pérez, A. Ponferrada, M. Van Domselaar, ML. Arias Rivera, O. Merino, E. Castro, JM. Marrero, M. Martín-Arranz, B. Botella, L. Fernández-Salazar, David Monfort, V. Opio, A. García-Herola, J. Llao, M. Menacho, P. Ramirez-de la Piscina, D. Ceballos, P. Almela, M. Navarro-Llavat, V. Robles-Alonso, AB Vega-López, JL Cabriada, MT Novella, C. Castaño-Milla, A. Sánchez-Torres, JM-Benítez, C. Rodríguez, E. Garrido, M. Mañosa and JP Gisbert. Evolution after anti-TNF discontinuation in patients with inflammatory bowel disease: a multicenter long-term follow-up study. Am J Gastroenterol 2017; 112: 120-131. Article.
  • JP Gisbert, J Molina-Infante. Tratamiento actual de la infección por Helicobacter pylori. Med Clin (Barc.) 2017; 148: 20-22. Editorial.
  • JP Gisbert. La relación mentor-aprendiz en medicina. Gastroenterol Hepatol 2017; 40: 48-57. Review.
  • J Molina-Infante, R Corti, AG McNicholl, JP Gisbert. Avances recientes en el tratamiento de la infección por Helicobacter pylori. Acta Gastroenterol Latinoam 2017; 47: 129-132. Review.
  • C Taxonera, E Iglesias, F Muñoz, M Calvo, M Barreiro-de Acosta, X Busquets, X Calvet, A Rodriguez, R Pajares, JP Gisbert, P Lopez-Serrano, JL Pérez-Calle, A Ponferrada, C De la Coba, F Bermejo, M Chaparro, C Alba, D Olivares, I Fernández-Blanco. Adalimumab maintenance treatment in ulcerative colitis: outcomes by prior anti-TNF use and efficacy of dose escalation. Dig Dis Sci 2017; 62:481-490. Article.
  • González-Lama, J. Sanz, G. Bastida, J. Campos, R. Ferreiro, B. Joven, A. Gutiérrez, X. Juanola, B. Sicilia, R. Veroz, J.P. Gisbert, M. Chaparro, E. Domènech, M. Esteve, F. Gomollón. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el tratamiento de pacientes con espondiloartritis asociada a enfermedad inflamatoria intestinal. Enferm inflam intest dia. 2017;16: 1-14. Review.
  • M Barreiro-de Acosta, JP Gisbert. Editorial: relative efficacy of infliximab and adalimumab in Crohn’s disease in an Australian and New Zealand cohort. Aliment Pharmacol Ther 2017; 45: 855-856. Letter.
  • ID Román, D Cano, MT Lobo, MD Fernández-Moreno, B Hernández-Breijo, P Sanmartín-Salinas, J Monserrat, JP Gisbert, LG Guijarro. Infliximab therapy reverses the increase of allograft inflammatory factor-1 in serum and colonic mucosa of rats with inflammatory bowel disease. Biomarkers 2017; 22: 133144. Article.
  • J Cubiella, A Castells, M Andreu, L Bujanda , F Carballo, R Jover, A Lanas, JD Morillas, D Salas, E Quintero; on behalf of the COLONPREV study investigators. Correlation between adenoma detection rate in colonoscopy- and fecal immunochemical testing-based colorectal cancer screening programs. United European Gastroenterology Journal 2017; 5: 255-260. Article.
  • S Khorrami, JP Gisbert. Accumulating data about ustekinumab in refractory Crohn’s disease in real world experience. Aliment Pharmacol Ther 2017; 45: 1374-1375. Letter.
  • AC Marin, OP Nyssen, AG McNicholl, JP Gisbert. Efficacy and safety of quinolone-containing rescue therapies after the failure of non-bismuth quadruple treatments for Helicobacter pylori eradication: Systematic review and meta-analysis. Drugs 2017; 77: 765-776. Seleccionado como open access gratuito por la revista Drugs.
  • O Companioni, JM Sanz-Anquela, ML Pardo, E Puigdecanet, L Nonell, N García, V Parra Blanco, C López, V Andreu, M Cuatrecasas, M Garmendia, JP Gisbert, C Gonzalez-Svatetz, N Sala. Gene expression study and pathway analysis of histological subtypes of intestinal metaplasia that progress to gastric cancer. PLoS One 2017; 12: e0176043. Article.
  • A López-Sanromán, I Vera-Mendoza, E Domènech, C Taxonera, V Vega, I Marín-Jiménez, J Guardiola, L Castro, M Esteve, E Iglesias, D Ceballos, P Martínez-Montiel, JP Gisbert, M Mínguez, A Echarri, X Calvet, J Barrio, J Hinojosa, MD Martín-Arranz, L Márquez-Mosquera, F Fermejo, J Rimola, V Pons, P Nos; Spanish APPRECIA GETECCU Group. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomized trial. J Crohns Colitis. En prensa. Article.
  • JP Gisbert, AG McNicholl. Optimization strategies aimed to increase the efficacy of pylori eradication therapies. Helicobacter. En prensa. Review.
  • P Valer, A Algaba, D Santos, ME Fuentes, E Nieto, JP Gisbert, P López, E Quintanilla, FG Alonso, I Guerra, Á Páez, F Bermejo. Evaluation of the Quality of Semen and Sexual Function in Men with Inflammatory Bowel Disease. Inflamm Bowel Dis. En prensa. Article.
  • M Iborra, JP Gisbert, MM Bosca-Watts, A López-García, V García-Sánchez, A López-Sanromán, E Hinojosa, L Márquez, S García-López, M Chaparro, M Aceituno, M Calafat, J Guardiola, B Belloc, Y Ber, Yolanda, L Bujanda, B Beltrán, C Rodríguez-Gutiérrez, J Barrio, JL Cabriada, M Rivero, R Camargo, M van Domselaar, A Villoria, H Salata Schuterman, D Hervás, P Nos, representing the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU). Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients. J Gastroenterol. En prensa. Article.
  • D Laharie, A Bourreille, J Branche, M Allez, Y Bouhnik, J Filippi, F Zerbib, G Savoye, L Vuitton, J Moreau, A Amiot, J Cosnes, E Ricart, O Dewit, A Lopez-Sanroman, JL Dupas, F Carbonnel, G Bommelaer, B Coffin, X Roblin, G van Assche, M Esteve, M Farkkila, JP Gisbert, P Marteau, S Nahon, M de Vos, J Lambert, JY Mary, E Louis. Long-term outcomes in a cohort of patients with acute severe ulcerative colitis refractory to intravenous steroids treated with ciclosporine or infliximab. Gut 2017. En prensa. Article.
  • M Chaparro, M Ramas, JM Benítez, A López-García, A Juna, J Guardiola, M Mínguez, X Calvet, L Márquez, LI Fernández Salazar, L Bujanda, A López-San Román, Y Zabana, R Lorente, J Barrio, J Hinojosa, M Iborra, M Domínguez Cajal, M Van Domselaar, MF García-Sepulcre, F Gomollón, M Piqueras, G Alcaín, V García-Sánchez, J Panés, E Domènech, E García-Esquinas, F Rodríguez-Artalejo, JP Gisbert. Extracolonic cancer in inflammatory bowel disease patients: data from the GETECCU ENEIDA registry. Am J Gastroenterol. En prensa. Article.
  • C Taxonera, A Ponferrada, F Bermejo, S Riestra, C Saro, MD Martín-Arranz, JL Cabriada, M Barreiro-de Acosta, ML de Castro, P López-Serrano, J Barrio, C Suarez, E Iglesias, F Argüelles-Arias, I Ferrer, I Marín-Jiménez, A Hernández-Camba, G Bastida, M Van Domselaar, P Martínez-Montiel, D Olivares, C Alba, JP Gisbert, on behalf of the SEGURTB study group from GETECCU. Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease. J Crohns Colitis. En prensa. Article.
  • F Fernandez-Bañares, M Piqueras, D Guagnozzi, V Robles, A Ruiz-Cerulla, MJ Casanova, JP Gisbert, D Busquets, Y Arguedas, A Pérez-Aisa, L Fernández-Salazar, AJ Lucendo for the GECM (Grupo Español de Colitis Microscópica). Collagenous colitis: requirement for high-dose budesonide as maintenance treatment. Dig Liver Dis. En prensa. Article.

 

 

  • M Aguas, P Nos, JP Gisbert. Letter: management of post-operative Crohn’s disease – thiopurines vs adalimumab. Aliment Pharmacol Ther 2016; 43: 168-169.
  • F Fernández-Bañares, MJ Casanova, Y Argüedas, B Beltrán, D Busquets, JM Fernández, L Fernández-Salazar, E García-Planella, D Guagnozzi, A Lucendo, N Manceñido, I Marín, M Montoro, M Piqueras, V Robles, A Ruiz-Cerulla, JP Gisbert. Spanish Microscopic Colitis Group (SMCG). Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group. Aliment Pharmacol Ther 2016; 43: 400-426. Article.
  • I Marín-Jiménez, P Nos, E Domenech, S Riestra, JP Gisbert, X Calvet, X Cortés, E Iglesias, JM Huguet, C Taxonera, R Fernández, D Carpio, A Gutiérrez, J Guardiola, L Castro, B Sicilia, L Bujanda, L Cea-Calvo, C Romero, O Rincón, B Juliá, J Panés. Diagnostic performance of the Simple Clinical Colitis Activity index self-administered online at home by patients with ulcerative colitis: CRONICA-UC study. Am J Gastroenterol 2016; 111: 261-268. Article.
  • JP Gisbert, M Barreiro, M Esteve, V García, F Gomollón, J Guardiola, J Hinojosa, MD Martín, M Mínguez, C Taxonera, M Vera. Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project. Inflam Bowel Dis 2016; 22: 583-598. Article.
  • M Lindo Ricce, V Martín Domínguez, Y Real, L González Moreno; C Constanza Martínez, C Humberto Gordillo Vélez, JP Gisbert. Colitis ulcerosa asociada a pancreatitis autoinmune, sialoadenitis y vasculitis leucocitoclástica. Gastroenterol Hepatol 2016; 39: 214-216. Article.
  • JP Gisbert, F Gomollón, I Méndez. Evaluación de coste-efectividad mediante análisis teórico de minimización de costes del uso de dos mesalazinas gastrorresistentes de liberación prolongada en el manejo de la colitis ulcerosa en España. Gastroenterol Hepatol 2016; 39: 199-212. Article.
  • I Guerra, T Pérez-Jéldres, M Iborra, A Algaba, D Monfort, X Calvet, M Chaparro, M Mañosa, E Hinojosa, M Mínguez, J Ortíz, L Márquez, V Prieto, V García-Sánchez, J Guardiola, E Rodriguez, MD Martín-Arranz, I García-Tercero, B Sicilia, MA Masedo, R Lorente, M Rivero, L Fernández, A Gutiérrez, M Van Domselaar, A López-SanRomán, Y Ber, MG Sepulcre, L Ramos, F Bermejo, JP Gisbert; Spanish GETECCU group (ENEIDA project). Incidence, clinical characteristics and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis 2016; 22: 894-901. Article.
  • N Piqué, M Ponce, V Garrigues, L Rodrigo, F Calvo, C Martín de Argila, F Borda, A Naranjo, J Alcedo, MJ Soria, E Rey, L Bujanda, JP Gisbert, D Suarez, X Calvet, J Ponce, on behalf of the PRESS Study Group. Prevalence of severe esophagitis in Spain. Results of the PRESS study (Prevalence and Risk factors for Esophagitis in Spain: A cross-sectional study. United European Gastroenterology Journal 2016; 4: 229-235. Article.
  • DS Bordin, OB Yanova, RA Abdulkhakov, VV Tsukanov, MA Livzan MA, SG Burkov SG, NV Zakharova, EY Plotnikova, MF Osipenko, LV Tarasova, IV Maev, YA Kucheryavyi, MA Butov, OA Sablin, SV Kolbasnikov, IN Voinovan, SR Abdulkhakov, AV Vasyutin, EA Lyalyukova, NN Golubev, IV Savilova, LV Grigor’eva, AG Kononova, CA O’Morain, M Ramas, AG Mcnicholl AG, Gisbert JP. European Registry on the management of Helicobacter pylori infection (Hp-EuReg protocol): The first results of Russian centers. Ter Arkh. 2016; 88: 33-38.
  • M Chaparro, M Barreiro-de Acosta, E Garcia-Planella, E Domènech, F Bermejo, X Calvet, MD Martín-Arranz, D Monfort, JP Gisbert. Outcome after a dose “de-intensification” strategy with anti-TNF drugs in patients with Crohn’s disease. Gastroenterol Hepatol 2016; 39: 255-260. Article.
  • JP Gisbert, M Chaparro. Switching from one to another anti-tumour necrosis factor alpha agent: the risks of an overlap of exposure – authors’ reply. Aliment Pharmacol Ther 2016; 1020. Letter.
  • C Alvarez-Urturi, M Andreu, C Hernandez, F Perez-Riquelme, F CarballO, A Ono, J Cruzado, J Cubiella, V Hernandez, CG Mao, E Perez, D Salas, M Andrés, L Bujanda, I Portillo, C Sarasqueta, E Quintero, JD Morillas, A Lanas, C Sostres, JM Augé, A Castells, X Bessa; COLONPREV study investigators. Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening. Dig Liver Dis 2016; 48: 542-551. Article.
  • CA González, JM Sanz-Anquela, O Companioni, C Bonet, M Berdasco, C López, J Mendoza, MD Martín-Arranz, E Rey, E Poves, L Espinosa, J Barrio, MÁ Torres, M Cuatrecasas, I Elizalde, L Bujanda, M Garmendia, Á Ferrández, G Muñoz, V Andreu, MJ Paules, S Lario, MJ Ramírez; JP Gisbert. Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study. J Gastroenterol Hepatol 2016; 31: 953-958. Article.
  • J Molina-Infante, A Lucendo, JP Gisbert. Letter: Helicobacter pylori infection and eosinophilic oesophagitis − causal or casual inverse association? Aliment Pharmacol Ther 2016; 43: 1244. Letter.
  • JP Gisbert, AC Marín, M Chaparro. The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: Systematic review and meta-analysis. Am J Gastroenterol 2016; 111:632-647. Article.
  • G Van Assche, L Peyrin-Biroulet, A Sturm, JP Gisbert, DR Gaya, B Bokemeyer, GJ Mantzaris, A Armuzzi, S Sebastian, N Lara, M Lynam, S Rojas-Farreras, T Fan, Q Ding, CM Black, S Kachroo. Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months – Multicenter European cohort study. Dig Liver Dis 2016; 48: 592-600. Article.
  • MC R-Grau, M Chaparro, F Mesonero, M Barreiro-de Acosta, L Castro, M Castro, E Domenech, N Manceñido, JL Pérez-Calle, C Taxonera, J Barrio, E De Francisco, E Fernández, L Luzón, O Merino, L Oltra, C Saro, F Bermejo, V García, D Ginard, A Gutiérrez, I Vera, R Antón, Y Ber, X Calvet, JP Gisbert. Effectiveness of anti-TNFα drugs in patients with Crohn’s disease who do not achieve remission with their first anti-TNFα agent. Dig Liver Dis 2016; 48: 613-619. Article.
  • C Taxonera, M Barreiro-de-Acosta, G Bastida, J Martínez-Gonzalez, O Merino, V García-Sánchez, JP Gisbert, I Marín-Jiménez, P López-Serrano, M Gómez-García, E Iglesias, A Lopez-Sanroman, M Chaparro, C Saro, F Bermejo, L Pérez-Carazo, R Plaza, D Olivares, C Alba, JL Mendoza, I Fernández-Blanco. Outcomes of medical and surgical therapy for entero-urinary fistulas in Crohn’s disease. J Crohns Colitis 2016; 10: 657-662.
  • M Chaparro, JP Gisbert. Maintenance therapy options for ulcerative colitis. Expert Op Pharmacother 2016; 17 1339-1349. Review.
  • L Peyrin-Biroulet, G Van Assche, A Sturm, JP Gisbert, DR Gaya, B Bokemeyer, GJ Mantzaris, S Sebastian, N Lara, M Lynam, S Rojas-Farreras, T Fan, Q Ding, C Black, S Kachroo. Treatment satisfaction, preferences and perception gaps between patients and physicians in the Ulcerative Colitis CARES Study: a Real world-based study. Dig Liver Dis 2016; 48: 601-607.
  • W Zabala, R Cruz, M Barreiro-de Acosta, M Chaparro, J Panés, A Echarri, M Esteve, D Carpio, M Andreu, E García-Planella, E Domènech, A Carracedo, JP Gisbert, F Barros on behalf of EIGA & ENEIDA investigators. Exome-wide pharmacogenomic analysis of response to thiopurines in inflammatory bowel disease patients. Current Pharmacogenomics and Personalized Medicine 2015; 13: 61-67 (DOI: 10.2174/1875692113666150813151413). Article.
  • I Puig, S Góngora, X Calvet, A Villoria, M Baylina, J Sánchez-Delgado, D Suárez, V García-Hernando, JP Gisbert. Systematic review: third-line susceptibility-guided treatment for pylori infection. Therap Adv Gastroenterol 2016; 9: 437-448. Article.
  • M Chaparro, JP Gisbert. New molecules in the treatment of inflammatory bowel disease. Gastroenterol Hepatol 2016; 39: 411-423. Review.
  • S Khorrami, D Ginard, I Marín-Jiménez, M Chaparro, M Sierra, M Aguas, B Sicilia, V García-Sánchez, C Suarez, A Villoria, C Taxonera, A Velasco-Guardado, J Martínez-González, JP Gisbert, on behalf of the USTEK Study Group. Ustekinumab for the treatment of refractory Crohn’s disease. The Spanish experience in a large multicentre open-label cohort. Inflam Bowel Dis 2016; 22: 1662-1669. Article.
  • CA Fallone, N Chiba, SV van Zanten, L Fischbach, JP Gisbert, R Hunt, N Jones, C Render, G Leontiadis, P Moayyedi, JK Marshall. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in adults. Gastroenterology 2016; 151: 51-69. Article. Seleccionado como Article de especial interés por “Medscape Gastroenterology” (http://www.medscape.com/viewarticle/862714).
  • S García-López, JM Bocos, JP Gisbert, E Bajador, M Chaparro, C Castaño, JA Garcia Erce, F Gomollón. High-dose intravenous treatment in iron deficiency anemia in inflammatory bowel disease: early efficacy and impact on quality of life. Blood Transfus 2016; 14: 199-205. Article.
  • R Jover, P Zapater, L Bujanda, V Hernandez, J Cubiella, M Pellise, et al. Endoscopist characteristics that influence the quality of colonoscopy. Endoscopy 2016; 48: 241-247. Article.
  • OP Nyssen, AG McNicholl, F Megraud, V Savarino, G Oderda, CA Fallone, L Fischbach, F Bazzoli, JP Gisbert. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2016 Jun 28;6:CD009034. Article.
  • AG McNicholl, JP Gisbert. In pylori-infected patients second-line treatment with sequential levofloxacin therapy was more effective than levofloxacin triple therapy but was still suboptimal. Evid Based Med 2016; 21: 144. Editorial.
  • F Casals, M Chaparro, J Maté, JP Gisbert. Clinical course of bone metabolism disorders in patients with inflammatory bowel disease: A 5-year prospective study. Inflamm Bowel Dis 2016; 22: 1929-1936. Article.
  • F Fernández-Bañares, JP Gisbert. Letter: oral low-dose methotrexate for collagenous colitis – authors’ reply. Aliment Pharmacol Ther 2016; 44: 98. Letter.
  • M Barreiro-de Acosta, JP Gisbert. Letter: anti-TNF in steroid-dependent ulcerative colitis – are the available data enough? Aliment Pharmacol Ther 2016; 44: 102. Letter.
  • A O’Connor, W Fischbach, JP Gisbert, CA O’Morain. Treatment of Helicobacter pylori Infection 2016. Helicobacter 2016; 21 (Suppl.1): 55-61. Review.
  • AG McNicholl, S Peña, JP Gisbert. Ensuring the highest eradication rates in pylori: the case of non-bismuth quadruple concomitant therapy. Eur J Intern Med 2016; 33: 1-2. Editorial.
  • Y González-Lama, JP Gisbert. Monitoring thiopurine metabolites in inflammatory bowel disease. Frontline Gastroenterology 2016; 7: 301-307. Review.
  • A Alonso, A Julià, M Vinaixa, E Domènech, A Fernández-Nebro, JD Cañete, C Ferrandiz, J Tornero, JP Gisbert, P Nos, AG Casbas, Puig L, I González-Alvaro, JA Pinto-Tasende, R Blanco, MA Rodríguez, A Beltrán, X Correig, S Marsal; IMID Consortium. Urine metabolome profiling in immune-mediated inflammatory diseases.BMC Med 2016; 14: doi: 10.1186/s12916-016-0681-8. Article.
  • J Panés, D García-Olmo, G Van Assche, JF Colombel, W Reinisch, DC Baumgart, A Dignass, M Nachury, M Ferrante, L Kazemi-Shirazi, JC Grimaud, F de la Portilla, E Goldin, MP Richard, A Leselbaum, S Danese,for the ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet 2016; 388: 1281-1290. Article.
  • I Puig, M Baylina, J Sánchez-Delgado, S Lopez-Gongora, D Suarez, P García-Iglesias, N Muñoz, JP Gisbert, C Dacoll, H Cohen, X Calvet. Systematic review and meta-analysis: Triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment. J Antimicrob Chemother 2016; 71: 2740-2753. Article.
  • P Miranda-García, M Chaparro, JP Gisbert. Correlation between serological biomarkers and endoscopic activity in patients with inflammatory bowel disease. Gastroenterol Hepatol 2016; 39: 50-515. Article.
  • BG Feagan, WJ Sandborn, C Gasink, D Jacobstein, Y Lang, JR Friedman, MA Blank, J Johanns, LL Gao, Y Miao, OJ Adedokun, BE Sands, SB Hanauer, S Vermeire, S Targan, S Ghosh, WJ de Villiers, JF Colombel, Z Tulassay, U Seidler, BA Salzberg, P Desreumaux, SD Lee, EV Loftus, Jr, LA Dieleman, S Katz, P Rutgeerts, for the UNITI–IM-UNITI Study Group. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med 2016; 375: 1946-1960. Article.
  • F Megraud, JP Gisbert. Towards effective empirical treatment for Helicobacter pylori eradication. Lancet 2016; 388: 2325-2326. Letter.
  • JE Domínguez-Muñoz, JP Gisbert. Últimas novedades presentadas en gastroenterología. Gastroenterol Hepatol 2016; 39 (Supl.1): 1-2.
  • JP Gisbert. Enfermedades relacionadas con la infección por pylori. Gastroenterol Hepatol 2016; 39 (Supl.1): 36-46. Review.
  • JP Gisbert, J Molina-Infante, J Amador, F Bermejo, L Bujanda, X Calvet, M Castro-Fernández, A Cuadrado-Lavín, JI Elizalde, E Gene, F Gomollón, A Lanas, C Martín de Argila, F Mearin, M Montoro, A Pérez-Aisa, E Pérez-Trallero, AG McNicholl. IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. Gastroenterol Hepatol 2016; 39: 697-721. Article.
  • E Domenech, JP Gisbert. Eficacia y seguridad de vedolizumab en el tratamiento de la colitis ulcerosa. Gastroenterol Hepatol 2016; 39: 677-686. Review.

 

  • C Castaño-Milla, M Chaparro, C Saro, M Barreiro-de Acosta, AM García-Albert, L Bujanda, MD Martín-Arranz, D Carpio, F Muñoz, N Manceñido, E García-Planella, M Piqueras, X Calvet, JL Cabriada, B Botella, F Bermejo, JP Gisbert. Effectiveness of Adalimumab in Perianal Fistulas in Crohn’s Disease Patients Naïve to Anti-TNF Therapy. J Clin Gastroenterol 2015; 49: 34-40. Article.
  • P Miranda-García, M Chaparro, JP Gisbert. Estudio de la concordancia entre la actividad clínica y los marcadores biológicos en la enfermedad inflamatoria intestinal. Med Clin (Barc) 2015; 144: 9-13. Article.
  • JP Gisbert. Is Less More: Does Leukopenia Predict Remission in Patients with Inflammatory Bowel Disease Receiving Thiopurine Treatment? Dig Dis Sci 2015; 60: 4-6. Editorial.
  • F Gomollón, S Rubio, M Charro, F Muñoz, S García, JP Gisbert, E Domènech. Recomendaciones del Grupo Español de Trabajo de Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el uso del Metotrexato en la Enfermedad Inflamatoria Intestinal. Gastroenterol Hepatol 2015; 38: 24-30. Article.
  • JM Benítez, V García-Sánchez, JP Gisbert. Letter: Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease. Aliment Pharmacol Ther 2015; 41: 494-495. Letter.
  • A Dignass, C Gasche, D Bettenworth, GBirgegård, S Danese, JP Gisbert, F Gomollon, T Iqbal, K Katsanos, I Koutroubakis, F Magro, G Savoye, J Stein, S Vavricka, on behalf of the European Crohn’s and Colitis Organisation (ECCO). European Consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015; 9: 211-222. Article.
  • JP Gisbert, AC Marín, AG McNicholl, M Chaparro. Efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed: a meta-analysis. Aliment Pharmacol Ther 2015; 41: 613-623. Seleccionado como una de las publicaciones más relevantes en MDLin Article.
  • MJ Casanova, M Chaparro, Valenzuela C, Cisneros C, JP Gisbert. Adalimumab-induced interstitial pneumonia in a patient with Crohn’s disease. World J Gastroenterol 2015; 21: 2260-2262. Article.
  • JP Gisbert, M Chaparro. Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it? Scand J Gastroenterol 2015; 50: 379-386. Review.
  • A Alonso, E Domènech, A Julià, J Panés, V García-Sánchez, P Nos Mateu, A Gutiérrez, F Gomollón, JL Mendoza, E Garcia-Planella, M Barreiro-de Acosta, F Muñoz, Ml Vera, C Saro, M Esteve, M Andreu, M Chaparro, J Manyé,E Cabré, M López-Lasanta, R Tortosa, JL Gelpí, AC García-Montero, J Bertanpetit, D Absher, R Myers, S Marsal, JP Gisbert. Identification of risk Loci for Crohn’s disease phenotypes using a genome-wide association study. Gastroenterology 2015; 148: 794-805. Article.
  • JP Gisbert, E Domenech. Vedolizumab en el tratamiento de la enfermedad de Crohn. Gastroenterol Hepatol 2015; 38: 338-348. Review.
  • D Kotlyar, JD Lewis, L Beaugerie, A Tierney, CM Brensinger, JP Gisbert, EV Loftus Jr, L Peyrin-Biroulet, W Blonski, M Van Domselaar, M Chaparro, S Sandilya, M Bewtra, F Beigel, L Biancone, GR Lichtenstein. Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Azathioprine and 6-Mercaptopurine: A Meta-analysis. Clin Gastroenterol Hepatol 2015; 13: 847-858.
  • E Rios, P Serón, JP Gisbert, X Bonfill. Endoscopic injection of cyanoacrylate glue vs. other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension. Cochrane Database Syst Rev. 2015 May 12;5:CD010180.
  • MJ Casanova, C Santander, JP Gisbert. Rectal hypersensitivity in patients with quiescent ulcerative colitis. J Crohns Colitis 2015; 9: 592. Letter.
  • A Díaz-Redondo, J Miranda, J García-Lledó, JP Gisbert, L Menchén. The potential usefulness of Human Leukocyte Antigen typing for celiac disease screening: a systematic review and meta-analysis. Rev Esp Enferm Dig 2015; 107: 423-429. Article.
  • JP Gisbert, AC Marín, M Chaparro. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. Aliment Pharmacol Ther 2015; 42: 391-405. Merecedor de un Comentario en com/Gastroenterology. Article.
  • JP Gisbert, M Chaparro. Letter: tumour necrosis factor alpha blocker switching–a not so simple pharmacokinetic. Authors’ reply. Aliment Pharmacol Ther 2015; 41: 1302-1303. Letter.
  • G D’Haens, WJ Sandborn, JF Colombel, P Rutgeerts, K Brown, H Barkay, A Sakov, A Haviv, BG Feagan. Laquinimod for Crohn’s Disease Investigators. A phase II study of laquinimod in Crohn’s disease. Gut 2015; 64:1227-1235. Article.
  • LM Medrano, C Taxonera, C González-Artacho, V Pascual, M Gómez-García, Barreiro-de Acosta, JL Pérez-Calle, F Bermejo, A López-Sanromán, D Martín Arranz, JP Gisbert, JL Mendoza, J Martín, C Núñez, E Urcelay. Response to infliximab in Crohn’s disease: genetic analysis supporting expression profile. Mediators of Inflammation 2015; Volume 2015, Article ID 318207: 1-8. Article.
  • M Chaparro, JP Gisbert. Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease – authors’ reply. Aliment Pharmacol Ther 2015; 42: 940-1. Letter.
  • C Taxonera, M Barreiro-de Acosta, M Calvo, C Saro, G Bastida, MD Martín-Arranz, JP Gisbert, V García-Sánchez, I Marín-Jiménez, F Bermejo, M Chaparro, A Ponferrada, P Martínez-Montiel, R Pajares, C. de Gracia, D Olivares, C Alba, JL Mendoza, I Fernández-Blanco. Infliximab dose escalation as an effective strategy for managing secondary loss of response in ulcerative colitis. Dig Dis Sci 2015; 60: 3075-3084. Article.
  • PM Linares, M Chaparro, A Algaba, M Román, I Moreno, F Abad Santos, D Ochoa, I Guerra, F Bermejo, JP Gisbert. Effect of chondroitin sulphate on pro-inflammatory mediators and disease activity in patients with inflammatory bowel disease. Digestion 2015; 92: 203-210. Article.
  • AC Marín, JP Gisbert, M Chaparro. Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease. World J Gastroenterol 2015; 21: 11273-11281. Review.
  • JE Domínguez-Muñoz, JP Gisbert. Últimas novedades presentadas en gastroenterología. Gastroenterol Hepatol 2015; 38 (Supl.1): 1-2.
  • I Marín-Jiménez, JP Gisbert, JL Pérez-Calle, V García-Sánchez, S Tabernero, R García-Vicuña, C Romero; B Juliá, F Vanaclocha, L Cea-Calvo; Investigadores del estudio AQUILES. Incidencia a los 2 años de nuevas enfermedades inflamatorias mediadas por inmunidad en la cohorte de pacientes con enfermedad inflamatoria intestinal del estudio AQUILES. Gastroenterol Hepatol 2015; 38: 569-574. Article.
  • J Gordillo, E Cabré, E Garcia-Planella, E Ricart, Y Ber-Nieto, L Márquez, F Rodríguez-Moranta, A Ponferrada, I Vera, JP Gisbert, J Barrio, M Esteve, O Merino, F Muñoz, E Domènech, on behalf of The ENEIDA Project of the Spanish Working Group in Crohn’s disease and Ulcerative Colitis (GETECCU). Thiopurine Therapy Reduces the Incidence of Colorectal Neoplasia in Patients with Ulcerative Colitis. Data from the ENEIDA Registry. J Crohns Colitis 2015; 9: 1063-1070. Article.
  • E Domenech, JP Gisbert. Eficacia y seguridad de vedolizumab en el tratamiento de la colitis ulcerosa. Gastroenterol Hepatol 2015; 38: 338-348. Review.
  • V Annese, L Beaugerie, L Egan, L Biancone, C Bolling, C Brandts, D Dierickx, R Dummer, G Fiorino, JM Gornet, P Higgins, KH Katsanos, L Nissen, G Pellino, G Rogler, F Scaldaferri, E Szymanska, R Eliakim; ECCO. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. J Crohns Colitis 2015; 9: 945-965.

 

  • MC Rodríguez-Grau, M Chaparro, R Díaz, JP Gisbert. Infliximab en el tratamiento de la enfermedad de Crohn gastroduodenal resistente. Gastroenterol Hepatol 2014; 37: 21-22.
  • LM Medrano, C Taxonera, A Márquez, M Barreiro-de Acosta, M Gómez-García, C González-Artacho, JL Pérez-Calle, F Bermejo, A Lopez-Sanromán, MD Martín Arranz, JP Gisbert, JL Mendoza, J Martín, E Urcelay, C Núñez. Role of TNFRSF1B polymorphisms in the response of Crohn’s disease patients to infliximab. Human Immunology 2014; 75: 71-75.
  • JP Gisbert, M Chaparro. Systematic review: Inflammatory bowel disease in the elderly Aliment Pharmacol Ther 2014; 39: 459-477. Seleccionado como una de las publicaciones más relevantes en MDLinx.
  • J Molina-Infante, X Calvet, JP Gisbert. Letter: The irony of oral iron – not an underdog for post-gastrointestinal bleeding anaemia. Aliment Pharmacol Ther 2014; 39: 550-551.
  • Y González-Lama, JP Gisbert. Letter: Metabolite monitoring for thiopurines in Crohn’s disease: Still not fully understood. Aliment Pharmacol Ther 2014; 39: 641.
  • C Castaño-Milla, M Chaparro, JP Gisbert. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative. Aliment Pharmacol Ther 2014; 39: 645-659. Article.
  • PM Linares, M Chaparro, JP Gisbert. Angiopoietins in inflammation and their implication in the development of inflammatory bowel disease. A review. J Crohns Colitis 2014; 8: 183-190.
  • M. Andreu, L. Marquez, E. Domènech, J.P. Gisbert, V. García, I. Marín, M. Peñalva, F. Gomollón, X. Calvet, O. Merino, E. García-Planella, N. Vazquez-Romero, M. Esteve, P. Nos, A. Gutierrez, I. Vera, JL. Cabriada, MD. Martín, N. Vázquez, J Panés on behalf of Spanish GETECCU group (ENEIDA project). Disease severity in familial cases of Inflammatory Bowel Disease. J Crohns Colitis 2014; 8: 234-239.
  • F Bermejo, A Algaba, I Guerra, JP Gisbert. Response to letter: folate deficiency in Crohn’s disease. Scand J Gastroenterol 2014; 49: 255-256.
  • Calvet, J Panés, N Alfaro, J Hinojosa, B Sicilia, M Gallego, I Pérez, P Lázaro de Mercado, F Gomollón. X. Aldeguera, R. Alos, M. Andreu, M. Barreiro, F. Bermejo, B. Casis, E. Domenech, E. Espin, M. Esteve, V. Garcia-Sanchez, A. Lopez-Sanroman, P. Martinez-Montiel, J. Luis Mendoza, J. P. Gisbert, M. Vera, A. Dosal, E. Sanchez, L. Marin, L. Sanroman, P. Pinilla, F. Murciano, A. Torrejon, J. Ramon Garcia, M. Ortega and J. Roldan. Delphi consensus statement: Quality indicators for Inflammatory Bowel Disease Comprehensive Care Units. J Crohns Colitis 2014; 8: 240-251.
  • A Algaba, PM Linares, ME Fernández-Contreras, A Figuerola, X Calvet, I Guerra, I de Pousa, M Chaparro, JP Gisbert, F Bermejo. The effects of infliximab or adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in inflammatory bowel disease: serial observations in 37 patients Inflamm Bowel Dis 2014; 20: 695-702.
  • E Cabré, M Mañosa, Ve García-Sánchez, A Gutiérrez, J Panés, M Esteve, M Peñalva, P Nos, O Merino, A Ponferrada, JP Gisbert, E Garcia-Planella, G Ceña, JL Cabriada, M Montoro, E Domènech, on behalf of the ENEIDA Project of the Spanish Working Group in Crohn’s Disease and Ulcerative Colitis (GETECCU). Phenotypic concordance in familial inflammatory bowel disease (IBD). Results of a nationwide IBD Spanish hospital database. J Crohns Colitis 2014; 8: 654-661.
  • M Barreiro-de Acosta, JP Gisbert. Letter: psychological remission: a future endpoint in inflammatory bowel disease? Aliment Pharmacol Ther 2014; 39: 1436.
  • M Chaparro, JP Gisbert. Limitations of studies to evaluate the significance of anti-tumor necrosis factor serum levels. Aliment Pharmacol Ther 2014; 40: 120-121.
  • F Fernandez-Bañares, JP Gisbert. Persisting clinical symptoms in microscopic colitis in remission. Aliment Pharmacol Ther 2014; 40: 117-118.
  • M Barreiro-de Acosta, JP Gisbert. Letter: Predictors of severe disease in ulcerative colitis −the same or different from in Crohn´s disease? Aliment Pharmacol Ther 2014; 40: 1120-1121.
  • A Cañas-Ventura, L Márquez, J Panés, E Domènech, JP Gisbert, V García-Sanchez, I Marín-Jiménez, F Rodriguez-Moranta, F Gomollón, X Calvet, O Merino, E Garcia-Planella, N Vázquez-Romero, M Esteve, P Nos, A Gutiérrez, M Vera, M Andreu, on behalf of Spanish GETECCU group (ENEIDA project). Risk of colectomy in patients with ulcerative colitis under thiopurine treatment. J Crohns Colitis 2014; 8: 1287-1293.
  • JE Domínguez-Muñoz, JP Gisbert. Últimas novedades presentadas en gastroenterología. Gastroenterol Hepatol 2014; 37 (Supl.3): 1-2.
  • M Vergara, C Bennett, X Calvet, JP Gisbert. Epinephrine injection versus epihephrine injection and a second endoscopic method in high risk bleeding ulcers (Cochrane Review). Cochrane Database Syst Rev. 2014 Oct 13;10:CD005584.
  • M Chaparro, JP Gisbert. How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease? Expert Opin Drug Saf. 2014; 13: 1749-1762.
  • C. Loras, J.P. Gisbert, M.C. Saro, M. Piqueras, C. Sánchez-Montes, J. Barrio, I. Ordás, A. Montserrat, R. Ferreiro, Y. Zabana, M. Chaparro, F. Fernández-Bañares,M. Esteve, for the REPENTINA study, GETECCU group (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa). Impact of surveillance of hepatitis B and hepatitis C in patients with inflammatory bowel disease under anti-tnf therapies: multicenter prospective observational study (Repentina 3). J Crohns Colitis 2014; 8: 1529-1538.
  • I Marín-Jiménez, V García Sánchez, JP Gisbert, JL Pérez Calle, M Luján, J Gordillo Ábalos, B Juliá, C Romero, L Cea-Calvo, R García-Vicuña, F Vanaclocha. Enfermedades inflamatorias mediadas por inmunidad en pacientes con enfermedad inflamatoria intestinal. Datos basales del estudio AQUILES. Gastroenterol Hepatol 2014; 37: 495-502.
  • D Cano-Martínez, ID Román, MVT Lobo, I Moreno-Villena, A Paradela, B Hernández-Breijo, MD Fernández-Moreno, J Monserrat, P Sanmartin-Salinas, JP Gisbert, LG Guijarro. Effect of infliximab in oxidised serum albumin levels during experimental colitis. Biomarkers 2014; 19: 693-701.
  • A Julià, E Domènech, M Chaparro, V García-Sánchez, F Gomollón, J Panés, M Mañosa, M Barreiro-de Acosta, A Gutiérrez, E Garcia-Planella, M Aguas, F Muñoz, M Esteve, JL Mendoza, M Vera, L Márquez, R Tortosa, M López-Lasanta, A Alonso, JLluís Gelpí, AC García-Montero, J Bertanpetit, D Absher, R Myers, JP Gisbert, S Marsal. A genome-wide association study identifies a novel locus at 6q22.1 associated with ulcerative colitis. Human Molecular Genetics 2014; 23: 6927-6934.
  • I Guerra, M Chaparro, F Bermejo, JP Gisbert. Measurement of Anti-TNF Agents and Anti-Drug Antibodies Serum Levels in Patients with Inflammatory Bowel Disease. Current Drug Metabolism 2014; 9: 875-881.

  •  JL Cabriada, I Vera, E Domènech, M Barreiro-de Acosta, M Esteve, JP Gisbert, J Panés, F Gomollón, en representación de GETECCU (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa). Recomendaciones para el uso de fármacos anti-TNF en la enfermedad inflamatoria intestinal. GETECCU 2013. Gastroenterol Hepatol 2013; 26: 127-146.
  • M González-Bárcenas, JP Gisbert, MA Romero-Ordóñez, F Fernández-Cano, R Rivera-Irigoin, JM Navarro-Jarabo, MC López-Vega, A Pérez-Aisa. Tratamiento de rescate con cuádruple terapia con bismuto tras el fracaso de 2 pautas terapéuticas en la erradicación de la infección por Helicobacter pylori. Revista de la Sociedad Andaluza de Patología Digestiva 2013; 36: 89-92.
  • JP Gisbert, X Calvet, F Bermejo, D Boixeda, F Bory, L Bujanda, M Castro-Fernández, E Dominguez-Muñoz, JI Elizalde, M Forné, E Gené, F Gomollón, A Lanas, C Martín de Argila, AG McNicholl, F Mearin, J Molina-Infante, M Montoro, JM Pajares, A Pérez-Aisa, E Pérez-Trallero, J Sánchez-Delgado. III Conferencia Española de Consenso sobre la infección por Helicobacter pylori. Gastroenterol Hepatol 2013; 36: 340-374.
  • J Molina-Infante, JP GisbertActualización de la eficacia de la terapia triple para la infección por Helicobacter pylori y de la resistencia a la claritromicina en España (2007-2012). Gastroenterol Hepatol 2013; 36: 375-381.
  • S Khorrami, D Ginard, JP GisbertComentario sobre el artículo: Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. Enfermedad Inflamatoria Intestinal al día 2013; Sección de Lectura Crítica de la Literatura. vol 12 (Nº 2): 121-123.
  • JP GisbertInformación al paciente: Linfoma gástrico MALT. Rev Esp Enferm Dig 2013; 105: 303.
  • F Gomollón, S García-López, B Sicilia, JP Gisbert, J Hinojosa, on behalf of GETECCU. The GETECCU clinical guideline for the treatment of ulcerative colitis: A guideline created using GRADE methodology. Gastroenterol Hepatol 2013; 36(7): 483.e1-483.e46.
  • JP Gisbert. Linfoma MALT gástrico. Rev Esp Enferm Dig 2013; 105: 303.
  • Mearin F, Barreiro-de Acosta M, Gonzalez-Galilea A, Gisbert JP, Cucala M, Ponce J. Prevalencia y características de la anemia y ferropenia enpacientes hospitalizados por enfermedades digestivas en España. Gastroenterol Hepatol 2013; 36: 499-507.
  • F Gomollón, S García-López, B Sicilia, JP Gisbert, J Hinojosa, on behalf of GETECCU. Guía de Práctica Clínica. Guía clínica GETECCU del tratamiento de la colitis ulcerosa elaborada con la metodología GRADE. Gastroenterol Hepatol 2013; 36: e1-e47.
  • JE Domínguez-Muñoz, JP GisbertÚltimas novedades presentadas en gastroenterología. Gastroenterol Hepatol 2013; 36 (Supl.2): 1-2.
  • JP GisbertEnfermedades relacionadas con la infección por H. pylori. Gastroenterol Hepatol 2013. 36 (supl.2): 39-50.       
  • F Bermejo, JP GisbertComentario sobre el artículo: Early Administration of Azathioprine vs Conventional Management of Crohn’s Disease: a Randomized Controlled Trial. Enfermedad Inflamatoria Intestinal al día 2013; Sección de Lectura Crítica de la Literatura. Vol. 12: 189-192.
  • M Chaparro, JP GisbertHepatitis B y C en pacientes con enfermedad inflamatoria intestinal. Proyecto Cátedra Innova. http://www.catedrainnova.es/
  • V Martín, AR Rubí, M Chaparro, V Jusué, A Friera, JP GisbertEmbolización arterial como tratamiento de la hemorragia digestiva baja masiva en pacientes con enfermedad de Crohn. Gastroenterol Hepatol 2013; 36: 574-576.
  • J Molina-Infante, JP GisbertProbióticos en el tratamiento erradicador de Helicobacter pylori: sin evidencia para su uso generalizado. Rev Esp Enferm Dig 2013; 105: 441-444.
  • M ChaparroJP GisbertLetter: measurement of anti-TNF-α levels and antibodies against the drug. Aliment Pharmacol Ther 2013; 37: 163-164.
  • E Domenech, JP GisbertShould colectomy be the end-point to evaluate the effectiveness of drug therapies in severe ulcerative colitis? Aliment Pharmacol Ther 2013; 37: 161-162.
  • F Megraud, S Coenen, A Versporten, M Kist, M Lopez-Brea, A Hirschl, L Andersen, H Goossens, Y Glupczynski, on behalf of the Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42.
  • I Guerra, JP GisbertOnset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agents. Expert Review Gastroenterol Hepatol 2013; 7: 41-48.
  • DY Graham, JP GisbertTailored therapy with novel sequential quadruple therapies. Nature Reviews Gastroenterol & Hepatol 2013; 10: 6-8.
  • C Taxonera, JP GisbertLetter: Recommendations for the management of latent tuberculosis infection in inflammatory bowel disease patients may not be applicable in all settings. Aliment Pharmacol Ther 2013; 37: 365-366.
  • F Fernández-Bañares, MR de Sousa, A Salas, B Beltrán, M Piqueras, E Iglesias, JP Gisbert, B Lobo, V Puig-Diví, E García-Planella, I Ordás, M Andreu, M Calvo, M Montoro, M Esteve, JM Viver, for the RECOMINA Project, GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa). Epidemiological risk factors in microscopic colitis: a prospective case-control study. Inflamm Bowel Dis 2013; 19: 411-417.
  • P Marticorena-Álvarez, M Chaparro, A Pérez-Casas, JP GisbertReply to Dr. Katsanos et al’s letter. J Crohn Colitis 2013; 7: e23-e24.
  • M Chaparro, M Trapero-Marugán, M Guijarro, R Moreno-Otero, JP GisbertDysplasia and colorectal cancer in a patient with ulcerative colitis and primary sclerosing cholangitis: a case report and a short review of the literature. J Crohn Colitis 2013; 7; e61-e65.
  • JP Gisbert, A Pérez-Aisa, F Bermejo, P Almela, M Castro-Fernández, J. Barrio, A. Cosme, F Bory, I Modolell,M Fernández-Bermejo, L Rodrigo, J Ortuño, P Sánchez-Pobre, S Khorrami, A Franco, I Guerra, E Lamas, A Tomas, J Ponce, X Calvet. Second-line rescue therapy with levofloxacin after failure of treatment to eradicate Helicobacter pylori infection: time trends in a Spanish multicenter study of 1,000 patients. J Clin Gastroenterol 2013; 47: 130-135. Seleccionado como una de las publicaciones más relevantes en MDLinx.
  • F Gomollón, JP GisbertIntravenous iron in inflammatory bowel diseases. Curr Opin Gastroenterol 2013; 29: 201-207.
  • R Moreno-Borque, JP Gisbert, C Santander. Pathophysiological bases of eosinophilic esophagitis therapy. Inflammation & Allergy – Drug Targets 2013; 12: 46-53.
  • F Fernández-Bañares, M Esteve, JP GisbertMucosal healing and mortality in coeliac disease. Aliment Pharmacol Ther 2013; 37: 760-761.
  • MJ CasanovaM Chaparro, E Domènech, M Mañosa, M Barreiro-de Acosta, F Bermejo, E Iglesias, F Gomollón, L Rodrigo, X Calvet , M Esteve, E García-Planella, S García, C Taxonera, M Calvo, JL Cabriada, D Ginard, M Gómez, E Garrido, JL Pérez-Calle, B Beltrán, M Piqueras, C Saro, B Botella, C Dueñas, A Ponferrada, V García, J Maté, JP GisbertSafety of thiopurines and anti-TNF-a drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 2013; 108: 433-440. Merecedor de un Editorial en Am J Gastroenterol. Seleccionado por “Faculty of 1000 Medicine (www.f1000medicine.com)” como uno de los mejores artículos.
  • JP Gisbert, JR Villagrasa, A Rodríguez-Nogueiras, M ChaparroKinetics of anti-hepatitis B surface antigen titers after hepatitis B vaccination in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 554-558.
  • R Jover, P Zapater, E Polanía, L Bujanda, ALanas, JA Hermo, J Cubiella, A Ono, Y González-Méndez, A Peris, M Pellisé, A Seoane, A Herreros, M Ponce, JC Marín-Gabriel, M Chaparro, G Cacho, S Fernández-Díez, J Arenas, F Sopeña, L de-Castro, P Vega-Villaamil, M Rodríguez-Soler, F Carballo, D Salas, JD Morillas, M Andreu, E Quintero, A Castells and COLONPREV study investigators. Modifiable endoscopic factors that influence the adenoma detection rate in colorectal cancer screening colonoscopies. Gastrointest Endosc 2013; 77: 381-389.
  • JP Gisbert, X Calvet. Review article: Helicobacter pylori “Test-and-Treat” strategy for management of dyspepsia: A comprehensive review. Clinical and Translational Gastroenterology 2013; Mar 28;4:e32. doi: 10.1038/ctg.2013.3.
  • M Chaparro, JP GisbertLetter: Dry blood spots for anti-TNF treatment monitoring in IBD  authors’ reply. Aliment Pharmacol Ther 2013; 37: 1025-1026.
  • PJ Kahrilas, C Howden, B Wernersson, H Denison, J Nuevo, JP GisbertImpact of persistent, frequent regurgitation on quality of life in heartburn responders treated with acid suppression in primary care: a multinational study. Aliment Pharmacol Ther 2013; 37: 1005-1010.
  • J Molina-Infante, JP GisbertLetter: Seeking oesophageal eosinophilia among unselected patients: looking for a needle in a haystack? Aliment Pharmacol Ther 2013; 37: 2029-1030.
  • M ChaparroJP GisbertResponse to Tung et al. Am J Gastroenterology 2013; 108: 621-622.
  • AC MarinAG McNichollJP GisbertA review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Op Pharmacother 2013; 14: 843-861.
  • W Zabala, R Cruz, M Barreiro-de Acosta, M Chaparro, J Panes, A Echarri, M Esteve, D Carpio, M Andreu, E García-Planella, E Domenech, A Carracedo, JP Gisbert, F Barros. New genetic associations in thiopurine related bone marrow toxicity among inflammatory bowel disease patients. Pharmacogenomics 2013; 14: 631-640.
  • JP GisbertM ChaparroVaccination strategies in patients with inflammatory bowel disease. Nature Reviews Gastroenterol & Hepatol 2013; 10: 277-285.
  • J Molina-Infante, DA Katzka, JP GisbertReview article: proton pump inhibitor therapy for suspected eosinophilic oesophagitis. Aliment Pharmacol Ther 2013; 37: 1157-1164.
  • J Molina-Infante, JP Gisbert. Quadruple therapy for Helicobacter pylori infection. Lancet 2013; 381: 1459.
  • M Chaparro, I Ordás, E Cabré, V García, G Bastida, M Peñalva, F Gomollón, E García-Planella, O Merino, A Gutiérrez, M Esteve, M Andreu, M Garcia-Sepulcre, J Hinojosa, I Vera, F Muñoz, JL Mendoza, JL Cabriada, MA Montoro, M Barreiro, G Ceña, C Saro, X Aldeguer, J Barrio, J MatéJP GisbertSafety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3,931 patients. Inflam Bowel Disease 2013; 19: 1404-1410.
  • F Fernández-Bañares, MR de Sousa, A Salas, B Beltrán, M Piqueras, E Iglesias, JP Gisbert, B Lobo, V Puig-Diví, E García-Planella, I Ordás, M Andreu, M Calvo, M Montoro, M Esteve, JM Viver for the RECOMINA Project, GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa). Impact of current smoking on the clinical course of microscopic colitis. Inflam Bowel Dis 2013; 19: 1470-1476.
  • M Barreiro-de Acosta, JP GisbertLetter: Mucosal healing in ulcerative colitis  Higher relevance than in Crohn’s disease? Aliment Pharmacol Ther 2013; 38: 207.
  • J Molina-Infante, JP GisbertCommentary: overcoming antibiotic resistance with Helicobacter pylori therapy – optimisation is the way forward. Aliment Pharmacol Ther 2013; 38: 204-205.
  • JP Gisbert, J Molina-Infante, AC Marín, G Vinagre, J Barrio, AG McNichollSecond-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple “sequential” or “concomitant” treatment to eradicate H. pylori infection. Scand J Gastroenterol 2013; 48: 652-656. Seleccionado como una de las publicaciones más relevantes en MDLinx.
  • J Molina-Infante, M Romano, M Fernandez-Bermejo, A Federico, AG Gravina, L Pozzati, E Garcia-Abadia, C Martinez-Alcala, G Vinagre-Rodriguez, M Hernandez-Alonso, A Miranda, JP GisbertOptimized Non-Bismuth Quadruple Therapies Cure Most Patients Infected with Helicobacter pylori in Populations with High Rates of Antibiotic Resistance. Gastroenterology 2013; 145: 121-128. Seleccionado para comentario en Diario Médico.
  • N Pedersen, A Bortoli, Duricova, R D´Inca, MR Panelli, JP Gisbert, G. Zoli, A. Lopez-Sanroman, F. Castiglione, G. Riegler, V. Annese, P. Gionchetti, A. Prada, E. D. Pont, A. Timmer, C. Felley, M. Shuhaibar, E. V. Tsianos, C. Dejaco, F. J. Baert, T. Jess, M. Lebech, D. W. Hommes & P. Munkholm on behalf of the European Crohn-Colitis Organisation (ECCO) study group of Epidemiology Committee (EpiCom). The course of inflammatory bowel disease during pregnancy and postpartum: A prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther 2013; 38: 501-512.
  • Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013; 369: 711-721.
  • Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369: 699-710.
  • O García-Bosch, JP Gisbert, M Andreu, O Merino, JL Cabriada, V García, A Gutiérrez, P Nos, M Peñalva, J Hinojosa, E García-Planella, F Muñoz, X Calvet, J Panés. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohn Colitis 2013; 7: 717-722.
  • M Calvino-Fernández, D. García-Fresnadillo, S Benito-Martínez, AG McNicholl, X Calvet, JP Gisbert, T Parra-Cid. H. pylori inactivation and virulence gene damage using a supported sensitiser for photodynamic therapy. Eur J Medic Chem 2013; 68: 284-290.
  • Castells A, Bessa X, Quintero E, Bujanda L, Cubiella J, Salas D, et al. Risk of advanced proximal neoplasms according to distal colorectal findings: comparison of sigmoidoscopy-based strategies. J Natl Cancer Inst 2013; 105: 878-886.
  • CA González, JM Sanz-Anquela, JP Gisbert, P Correa. Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. Int J Cancer 2013; 133: 1023-1033.
  • T Nunes, MJ Etchevers, E Domenech, V Garcia-Sanchez, Y Ber, M Penalva, O Merino, P Nos, E Garcia-Planella, A Gutierrez, M Esteve, C Taxonera, M Montoro, JP Gisbert, MD Martin Arranz, M F. Garcia-Sepulcre, M Barreiro-de Acosta, B Beltran, N Alcaide, C Saro, J Cabriada, A Canas-Ventura, F Gomollon, J Panes. Smoking does influence disease behavior and impacts the need for therapy in Crohn´s disease in the biologic era. Aliment Phamacol Ther 2013; 38: 752-760.
  • A O’Connor, J Molina-Infante, JP Gisbert, CA O’Morain. Treatment of Helicobacter pylori Infection 2013; 18 (suppl.1): 58-65.
  • A Julià, E Domènech, E Ricart, R Tortosa, V García, JP Gisbert, P Nos, A Gutiérrez, F Gomollón, JL Mendoza, E García-Planella, M Barreiro, F Muñoz, M Vera, C Saro, M Esteve, M Andreu, A Alonso, M López-Lasanta, L Codó, JL Gelpí, AC García-Montero, J Bertanpetit, D Absher, J Panés, S Marsal. Genome-wide association study identifies a new Crohn’s Disease susceptibility locus at RBX1-EP300. Gut 2013; 62: 1440-1445.
  • JP GisbertM ChaparroSafety of anti-TNF agents during pregnancy and breast-feeding in women with inflammatory bowel disease. Am J Gastroenterol 2013; 108: 1426-1438. Seleccionado como una de las publicaciones más relevantes en MDLinx.
  • B Hernández-Breijo, J Monserrat, ID Román, A González-Rodríguez, MD Fernández-Moreno, AM Valverde, JP Gisbert, LG Guijarro. Azathioprine desensitizes hepatoblastoma cells to insulin-like growth factor 1 and causes apoptosis when it is combined with bafilomycin A1. Toxicology and Applied Pharmacology; 272: 568-578.
  • A Algaba, PM Linares, ME Fernández Contreras, A Ordoñez, J Trápaga, I Guerra, M Chaparro, G de la Poza, JP Gisbert, F Bermejo. Relationship between levels of angiogenic and lymphangiogenic factors and the endoscopic, histological and clinical activity, and acute phase reactants in patients with inflammatory bowel disease. J Crohns Colitis, 2013 Dec 1;7(11).
  • J Panés, A López-San Román, F Bermejo, V García-Sánchez, M Esteve, Y Torres, E Domenech, M Piqueras, M Gomez-Garcia, A Gutiérrez, C Taxonera, M Sans for the AZTEC study group. Early Azathioprine Therapy is no More Effective Than Placebo for Newly Diagnosed Crohn’s Disease. Gastroenterology 2013; 145: 766-774.
  • Álvarez C, Andreu M, Castells A, Quintero E, Bujanda L, Cubiella J, Salas D, Lanas Á, Carballo F, Morillas JD, Hernández C, Jover R, Sarasqueta C, Enriquéz-Navascués JM, Hernández V, Estévez P, Macenlle R, Sala T, Balaguer F, Pellisé M, Moreira L, Gil I, Peris A, González-Rubio F, Ferrández A, Poves C, Ponce M, Grau J, Serradesanferm A, Ono A, Cruzado J, Pérez-Riquelme F, Alonso-Abreu I, Carrillo-Palau M, Santander C, Díaz Tasende J, Herreros A, Cacho G, Barranco LE, Bessa X; ColonPrev study investigators. Relationship of colonoscopy-detected serrated polyps with synchronous advanced neoplasia in average-risk individuals. Gastrointest Endosc 2013; 78: 333-341.
  • A Lopez-Sanroman, JP GisbertLetter: ciclosporin of infliximab in acute ulcerative colitis − still undecided. Aliment Pharmacol Ther 2013;           38: 992.
  • F Bermejo, A Algaba, M Chaparro, I Guerra, G De-La-Poza, JP GisbertShould we monitor vitamin B12 and folate levels in Crohn’s disease patients? Scand J Gastroenterol 2013; 48: 1272-1277.
  • F Bermejo, A Algaba, M Chaparro, C Taxonera, A López-Sanromán, I Guerra, JP Gisbert, D Olivares, E Garrido, G de-la-Poza, I García-Arata. How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients under anti-TNF treatment? A pilot study. Dig Liver Dis 2013; 45: 733-737.
  • F Gomollón, JP GisbertCurrent management of iron deficiency anemia in inflammatory bowel diseases: a practical guide. Drugs 2013; 73: 1761-1770.
  • M Barreiro-de Acosta, JP GisbertLetter: Infliximab in severe ulcerative colitis − is it useful for all patients? Aliment Pharmacol Ther 2013; 38: 1413.
  • J Molina-Infante, SD Georgopoulos, JP GisbertLetter: Concomitant therapy for H. pylori infection is superior to sequential therapy if they are fairly compared. BMJ 2013; 17 Aug.
  • M Chaparro, C Zanotti, P Burgueño, I Vera, F Bermejo, I Marín-Jiménez, C Yela, P López, MD Martín, C Taxonera, B Botella, R Pajares, A Ponferrada, M Calvo, A Algaba, L Pérez, B Casis, J Maté, J Orofino, N Lara, M García-Losa, X Badia,JP GisbertHealth care cost of complex perianal fistula in Crohn’s disease. Dig Dis Sci 2013; 58: 3400-3406.
  • M Barreiro-de Acosta, JP GisbertLetter: Acute severe ulcerative colitis − Should all the patients be treated equally? Aliment Pharmacol Ther 2013; 39: 113.
  • J Molina-Infante, JP GisbertLetter: PPI-responsive oesophageal esinophilia  from initial scepticism to consistent prospective data. Aliment Pharmacol Ther 2013; 39: 229-230.
  • LM Medrano, C Taxonera, A Márquez, M Barreiro-de Acosta, M Gómez-García, C González-Artacho, JL Pérez-Calle, F Bermejo, A Lopez-Sanromán, MD Martín Arranz, JP Gisbert, JL Mendoza, J Martín, E Urcelay, C Núñez. Role of TNFRSF1B polymorphisms in the response of Crohn´s disease patients to infliximab. Human Immunology 2013; 75: 71-75.
  • AG McNichollAC Marin, J Molina-Infante, M Castro, J Barrio, J Ducons, X Calvet, C de la Coba, M Montoro, F Bory, A Perez-Aisa, M Forné, M Ramas, R Millán, P Aranguren, P García Iglesia, B Belloc, X Bessa, E Sainz, JL Gisbert, E Lamas, A Figuerola, C Álvarez, S Marcos, MI Moreno, F Abad-Santos, JP GisbertRandomized clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2014; 63: 244-249. Seleccionado como una de las publicaciones más relevantes en MDLinx. Seleccionado por “Faculty of 1000 Medicine (www.f1000medicine.com)” como uno de los mejores artículos.
  • Y Yuan, AC Ford, KJ Khan, JP Gisbert, D Forman, GI Leontiadis, F Tse, X Calvet, C Fallone, L Fischbach, G Oderda, F Bazzoli, P Moayyedi. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013 Dec 11;12:CD008337.
  • F Juliao, J Marquez, N Aristizabal, C Yepes, J Zuleta, JP GisbertClinical Efficacy of Infliximab in Moderate to Severe Ulcerative Colitis in a Latin American Referral Population. Digestion 2013; 88: 222-228.
  • J Molina-Infante, M Romano, JP Gisbert. Reply to Georgopoulos et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013; 145: 1497-1498.

  • JP GisbertM ChaparroPuesta al día Eneida. Newsletter ENEIDA. Pags 5-7.
  • M ChaparroJP GisbertDiagnóstico diferencial de las estenosis intestinales y su manejo en los pacientes con enfermedad de Crohn. En: Diagnóstico diferencial de la enfermedad inflamatoria intestinal. I Marín, L Menchén, F Gomollón Eds. Elsevier Doyma 2012: pags 75-86.
  • M ChaparroJP GisbertPapel de los fármacos tiopurínicos en la colitis ulcerosa. Gastroenterol Hepatol 2011; 34 (suppl.3): 30-35.
  • M ChaparroJP GisbertActualización del tratamiento médico de la enfermedad de Crohn. Medicine 2012; 11: 284-292.
  • M ChaparroJP GisbertTratamiento del brote de la enfermedad de Crohn. Medicine 2012; 11: 309-313.
  • E Ricart, JP GisbertComentario sobre el artículo: Switch to adalimumab in patients with Crohn’s disease controlled by maintenance infliximab. The prospective randomized SWITCH trial. Enfermedad Inflamatoria Intestinal al día 2012; Sección de Lectura Crítica de la Literatura. vol 11 (Nº 2): 163-166.
  • A Perez-Aisa, J Nuevo, AJ Lopez-Morante, A Gonzalez-Galilea, C Martin de Argila, D Aviñoa Arreal, F Feu, F Borda Celaya, JP Gisbert, F Perez-Roldan, JM Gonzalvo-Sorribes, JM Palazon- Azorin, M Ponce –Romero, M Castro-Fernandez, MV Catalina-Rodriguez, S Gallego-Monatñes, X Calvet, L Rodrigo Saez, M Montoro-Huguet, Y González-Méndez, A Sierra-Hernández, E Sánchez-Hernández, E Pérez-Cuadrado, M Muñoz, A Lanas. Situación actual del manejo de la hemorragia digestiva alta no varicosa en España. Gastroenterol Hepatol 2012; 35: 468-475.
  • M ChaparroJP GisbertTratamiento actual de las enfermedades inflamatorias intestinales crónicas. Blastonterología. Nº3, enero 2012: 2-4.
  • J Martin de Carpi, JP GisbertComentario sobre el artículo: A preliminary trial of the effect of recombinant human growth hormone on short-term linear growth and glucose homeostasis in children with Crohn’s disease. Enfermedad Inflamatoria Intestinal al día 2012; Sección de Lectura Crítica de la Literatura; Vol. 11. Nº 3: 237-241.
  • JE Domínguez-Muñoz, JP GisbertÚltimas novedades presentadas en gastroenterología. Gastroenterol Hepatol 2012; 35 (supl.1): 1-2.
  • JP GisbertEnfermedades relacionadas con la infección por H. pylori. Gastroenterol Hepatol 2012. 35 (supl.1): 12-25.
  • JP Gisbert, X Calvet, J Ferrándiz, J Mascort, P Alonso-Coello, M Marzo. Guía de Práctica Clínica sobre el manejo del paciente con dispesia. Actualización 2012. Gastroenterol Hepatol 2012; 35: 725.e1-725.e38.
  • JP Gisbert, X Calvet, J Ferrándiz, J Mascort, P Alonso-Coello, M Marzo. Guía de Práctica Clínica sobre el manejo del paciente con dispesia. Actualización 2012. Aten Primaria 2012; 44: 727.e1-727.e38.
  • JP Gisbert, X Calvet, J Ferrándiz, J Mascort, P Alonso-Coello, M Marzo. Manejo del paciente con dispepsia. Guía de práctica clínica. Actualización 2012. Resumen ejecutivo. Aten Primaria 2012; 44: 728-733.
  • F Gomollón, S García-López, B Sicilia, JP Gisbert, J Hinojosa, on behalf of GETECCU. Therapeutic Guidelines on Ulcerative Colitis: a GRADE methodology based effort of GETECCU. Gastroenterol Hepatol 2013; 35: 104-114. Incluido en el catálogo GuiaSalud.
  • Grupo de trabajo de la guia de practica clinica sobre dispepsia. Manejo del paciente con dispepsia. Guia de practica clinica. Barcelona: Asociacion Espanola de Gastroenterologia, Sociedad Espanola de Medicina de Familia y Comunitaria y Centro Cochrane Iberoamericano; Actualizacion 2011. Programa de Elaboracion de Guias de Practica Clinica en Enfermedades Digestivas, desde la Atencion Primaria a la Especializada: 3. Incluido en el catálogo GuiaSalud, disponible en: http://portal.guiasalud.es/web/guest/catalogo-gpc.
  • E Garrido, JP Gisbert. Comentario sobre el artículo: Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Enfermedad Inflamatoria Intestinal al día 2012; Sección de Lectura Crítica de la Literatura; Vol. 12. Nº 1: 58-60.
  • M Chaparro, P Burgueño, E Iglesias, J Panés, F Muñoz, P Nos, L Castro, C Jiménez, JL Mendoza, M Barreiro, S Gómez Senent, F Gomollón, X Calvet, E García-Planella, M Gómez, V Hernández, J Hinojosa, M Mañosa, O Pérez Nyssen, JP GisbertInfliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. Aliment Pharmacol Ther 2012; 35: 275-283. Merecedor de un Comentario en la sección Research Highlight de Nature Reviews Gastroenterology & Hepatology titulado: “Ulcerative colitis: Administering infliximab after ciclosporin”.
  • JP Gisbert, X Calvet. Review article: Rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 35: 209-221.
  • Y González-Lama, JP GisbertWhy Thiopurine metabolites are relevant: authors’ reply. Aliment Pharmacol Ther 2012; 35: 401-402.
  • M Chaparro, P Martínez-Montiel, M Van-Domselaar, F Bermejo, JL Pérez-Calle, B Casis, A López-SanRomán, A Algaba, J MatéJP GisbertIntensification of infliximab therapy in Crohn’s disease: efficacy and safety. J Crohn’s Colitis 2012; 6: 62-67.
  • Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, Andreu M, Carballo F, Morillas JD, Hernández C, Jover R, Montalvo I, Arenas J, Laredo E, Hernández V, Iglesias F, Cid E, Zubizarreta R, Sala T, Ponce M, Andrés M, Teruel G, Peris A, Roncales MP, Polo-Tomás M, Bessa X, Ferrer-Armengou O, Grau J, Serradesanferm A, Ono A, Cruzado J, Pérez-Riquelme F, Alonso-Abreu I, de la Vega-Prieto M, Reyes-Melian JM, Cacho G, Díaz-Tasende J, Herreros-de-Tejada A, Poves C, Santander C, González-Navarro A; COLONPREV Study Investigators. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012; 366: 697-706.
  • JP GisbertRescue therapy for Helicobacter pylori infection 2012. Gastroenterol Research Practice 2012; Article ID 974594, doi:10.1155/2012/974594.
  • JP GisbertAG McNichollMaintenance of Helicobacter pylori eradication rates with triple therapy over 12 years in a Spanish hospital. Helicobacter 2012; 17: 160-161.
  • JP Gisbert, X Calvet. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Experimental Gastroenterol 2012; 5: 23-34. Seleccionado como una de las publicaciones más relevantes en MDLinx.
  • G de la Poza, A Lopez-Sanroman, C Taxonera, I Marín, JP Gisbert, F Bermejo, V Opio, A Muriel. Genital fistulas in female Crohn’s disease patients. Clinical characteristics and response to therapy. J Crohn Colitis 2012; 6: 276-280.
  • JP GisbertThe ethics of using inferior regimens in H. pylori randomised trials – invited comment. Aliment Pharmacol Ther 2012; 35: 856-857.
  • M Chaparro, J Panés, V García, O Merino, P Nos, E Domènech, M Peñalva, E García-Planella, M Esteve, J Hinojosa, M Andreu, F Muñoz, A Gutiérrez, JL Mendoza, J Barrio, M Barreiro, I Vera, P Vilar, JL Cabriada, MA Montoro, X Aldeguer, C Saro, JP Gisbert. Long-term durability of response to adalimumab in Crohn’s disease. Inflam Bowel Dis 2012; 18: 685-690.
  • JP Gisbert, M Castro-Fernandez, A Perez Aisa, A Cosme, J Molina-Infante, L Rodrigo, I Modolell, JL Cabriada, JL Gisbert, E Lamas, E Marcos, X Calvet. Fourth-line rescue therapy with rifabutin in patients with three H. pylori eradication failures. Aliment Pharmacol Ther 2012; 35: 941-947. Merecedor de un Comentario en la sección Research Highlight de Nature Reviews Gastroenterology & Hepatology. Seleccionado como una de las publicaciones más relevantes en MDLinx.
  • P Malfertheiner, F Megraud, C O’Morain, J Atherton, A Axon, F Bazzoli, E El-Omar, G Gensini, JP Gisbert, D Graham, T Rokkas, E Kuipers & the European Helicobacter Study Group (EHPSG). Management of Helicobacter pylori infection–the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-664. Seleccionado por “Faculty of 1000 Medicine (www.f1000medicine.com)” como uno de los mejores artículos.
  • M Chaparro, I Guerra, PM LinaresJP GisbertSystematic review: Antibodies and anti-TNF-α levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 971-986.
  • A Barbero-Villares, J Mendoza, C Taxonera, A López-Sanromán, R Pajares, F Bermejo, JL Pérez-Calle, R Moreno-Otero, JL Mendoza, J MatéJP GisbertOn behalf of the Madrid Group for the Study of Inflammatory Bowel Disease (ENICMAD). Evaluation of liver fibrosis by transient elastography (Fibroscan) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial. Scand J Gastroenterol 2012; 47: 575-579.
  • M Román, T Cabaleiro, J Novalbos, M ChaparroJP Gisbert, F Abad-Santos. Validation of a genotyping method for analysis of TPMT polymorphisms. Clin Ther 2012; 34: 878-884.
  • JP Gisbert, L Menchén, V García-Sánchez, I Marín, JR Villagrasa, M ChaparroComparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 1379-1385. Merecedor de un Comentario en la sección Research Highlight de Nature Reviews Gastroenterology & Hepatology titulado: “Optimizing vaccination strategies against HBV in patients with IBD ”. Seleccionado como una de las publicaciones más relevantes en MDLinx.
  • I. Guerra, A. Algaba, J. Pérez-Calle, M. Chaparro, I. Marín-Jiménez, A. López-Sanromán, R. García-Castellanos, Y. González-Lama, N. Manceñido, P. Martínez, E. Quintanilla, C. Taxonera, M. Villafruela, A. Romero, P. López-Serrano, J. P. Gisbert, F. Bermejo. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohn Colitis 2012; 6: 518-523.
  • JP Gisbert on behalf of the H. pylori Study Group of the Spanish Gastroenterology Association. Third-line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 35: 1484-1485.
  • Y Gonzalez-Lama, JP GisbertTPMT − not all that glitters is gold. Aliment Pharmacol Ther 2012; 36: 208-209.
  • J Sánchez-Delgado, P García-Iglesias, M Castro-Fernández, F Bory, M Barenys, L Bujanda, J Lisozain, MM Calvo, S Torra, JP Gisbert, X Calvet. Clinical trial. High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high H. pylori eradication rates. Aliment Pharmacol Ther 2012; 36: 190-196.
  • J Molina-Infante, C Pazos-Pacheco, G Vinagre-Rodriguez, B Perez-Gallardo, C Dueñas-Sadornil, M Hernandez-Alonso, G Gonzalez-Garcia, JM Mateos-Rodriguez, M Fernandez-Bermejo, JP GisbertNon-bismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and vs. sequential therapy for clarithromycin-resistant strains. Helicobacter 2012; 17: 269-276.
  • M Barreiro-de Acosta, JP GisbertLetter: Surgery for ulcerative colitis mostly follows anti-TNF drugs – a new ‘therapeutic package’? Aliment Pharmacol Ther 2012; 36: 297-298.
  • AG McNichollJP GisbertCommentary: Comparators in H. pylori eradication  Stating the ethics of statins. Aliment Pharmacol Ther 2012; 36: 400-401.
  • F Bermejo, E Garrido, M Chaparro, J Gordillo, M Mañosa, A Algaba, A López-Sanromán, JP Gisbert, E. García-Planella, E Doménech, I Guerra. Efficacy of different therapeutic options for spontaneous abdominal abscesses in Crohn’s disease: are antibiotics enough? Inflamm Bowel Dis 2012; 18: 1509-1514.
  • B Velayos, L Fernández-Salazar, F Pons-Renedo, MF Muñoz, A Almaraz, R Aller, L Ruíz, L Del Olmo, JP Gisbert, JM González-Hernández. Accuracy of urea breath test performed immediately after emergency endoscopy in peptic ulcer bleeding. Dig Dis Sci 2012; 57: 1880-1886.
  • J Hinojosa, JP Gisbert, F Gomollon, AL San Roman. Adherence of gastroenterologists to European Crohn’s and Colitis Organisation consensus on Crohn’s disease: A real-life survey in Spain. J Crohn Colitis 2012; 6: 763-770.
  • Y González-Lama, C Taxonera, A López-Sanromán, JL Pérez-Calle, F Bermejo, R Pajares, AG McNicholl, V Opio, JL Mendoza, P López, A Algaba, J Estelles, A Barbero, JL Mendoza, J Maté, JP GisbertMethotrexate in inflammatory bowel disease: A multicenter retrospective study focused on long-term efficacy and safety. The Madrid experience. Eur J Gastroenterol Hepatol 2012; 24: 1086-1091.
  • AG McNichollPM Linares, OP Nyssen, X Calvet, JP GisbertMeta-analysis: esomeprazole or rabeprazole vs. first generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36: 414-425. Seleccionado por “Faculty of 1000 Medicine (www.f1000medicine.com)” como uno de los mejores artículos.
  • I Guerra, JP GisbertLetter: Anti-TNFs and psoriasis: friends or foes? Aliment Pharmacol Ther 2012; 36: 497.
  • A Lopez-Sanroman, JP GisbertInfliximab and adalimumab in the management of Crohn’s disease: are they really comparable? Aliment Pharmacol Ther 2012; 36: 498-499.
  • JP Gisbert, X Calvet, A Cosme, P Almela, F Feu, F Bory, S Santolaria, R Aznárez, M Castro, N Fernández, R García-Grávalos, A Benages, N Cañete, M Montoro, F Borda, A Pérez-Aisa, JM Piqué. Long-Term Follow-Up of 1,000 Patients Cured of Helicobacter pylori Infection Following an Episode of Peptic Ulcer Bleeding. Am J Gastroenterol 2012; 107: 1197-1204. Merecedor de un Comentario en Journal Watch Gastroenterology.
  • X Calvet, JP GisbertLetter: Are idiopathic (non-NSAID, non-H. pylori) ulcers really increasing? Aliment Pharmacol Ther 2012; 36: 600-601.
  • F Fernández-Bañares, JP GisbertAre lymphocytic colitis and collagenous colitis really the same disease? Aliment Pharmacol Ther 2012; 36: 600-601.
  • P Marticorena-Álvarez, M Chaparro, A Pérez-Casas, MA Muriel-Herrero, JP GisbertProbable diffuse retinopathy caused by adalimumab in a patient with Crohn’s disease. J Crohn Colitis 2012; 6: 950-953.
  • E Domenech, JP GisbertReal-life management of new onset ulcerative colitis and proctitis. Aliment Pharmacol Ther 2012; 36: 685-686.
  • F Gomollon, JP GisbertIntravenous iron in digestive diseases. Transfusion Alternatives in Transfusion. Medicine 2012; 12: 122-129.
  • M ChaparroJP GisbertMucosal PCR for cytomegalovirus in refractory ulcerative colitis. Aliment Pharmacol Ther 2012; 36: 812.
  • B Tepes, A O’Connor, JP Gisbert, CA O’Morain. Treatment of Helicobacter pylori. Infection 2012; 17 (suppl.1): 36-42.
  • JP Gisbert, JR Villagrasa, A Rodríguez-Nogueiras, M ChaparroEfficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol 2012; 107: 1460-1466.
  • M Chaparro, M Andreu, M Barreiro, E García-Planella, E Ricart, E Doménech, M Esteve, O Merino, P Nos, M Peñalva, JP GisbertEffectiveness of infliximab after adalimumab failure in Crohn’s disease. World J Gastroenterol 2012; 18: 5219-5224.
  • WJ Sandborn, C Gasink, LL Gao, MA Blank, J Johanns, C Guzzo, BE Sands, SB Hanauer, St Targan, P Rutgeerts, S Ghosh, WJS de Villiers,R Panaccione, G Greenberg, S Schreiber, S Lichtiger, BG Feagan, for the CERTIFI Study Group. Ustekinumab Induction and Maintenance Therapy in Refractory Crohn’s Disease. N Engl J Med 2012; 367: 1519-1528.
  • L Katz, JP Gisbert, B Manoogian, L Kirk, C Steenholdt, GJ Mantzaris, A Atreja, Y Ron, A Swaminath, S Shah, A Harts, PL Lakatos, P Ellul, E Israeli, MN Svendsen, J van der Woude, KH Katsanos, L Yun, EV Tsianos, T Nathan, M Abreu, I Dotan, B Lashner, J Brynskov, JP Terdiman, P Higgins, M Chaparro, S Ben-Horin. Doubling the infliximab dose versus halving the infusion intervals in Crohn’s disease patients with loss of response. Inflamm Bowel Dis 2012; 18: 2026-2033.
  • MJ CasanovaM Chaparro, S Martínez, I Vicuña, JP GisbertSevere adalimumab-induced thrombocytopenia in a patient with Crohn’s disease. J Crohn’s Colitis 2012; 6: 1034-1037.
  • D Laharie, A Bourreille, J Branche, M Allez, Y Bouhnik, J Filippi, F Zerbib, M Nachury, G Savoye, J Moreau, JC Delchier, E Ricart, J Cosnes, A López-Sanroman, O Dewit, JL Dupas, F Carbonnel, G Bommelaer, B Coffin, X Roblin, G Van Assche, M Esteve, M Färkkilä, JP Gisbert, P Marteau, S Nahon, M de Vos, D Franchimont, JY Mary, JF Colombel, M Lémann. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-1915. Seleccionado por “Faculty of 1000 Medicine (www.f1000medicine.com)” como uno de los mejores artículos.
  • JP GisbertDrugs and the Upper and Lower Gastrointestinal Tract: From Inflammation to Malignancy. Curr Drug Metab 2012; 13: 1266.
  • LG Guijarro, ID Román, MD Fernández-Moreno, JP Gisbert, B Hernández-Breijo. Is the autophagy induced by thiopurines beneficial or deleterious? Curr Drug Metab 2012; 13: 1267-1276.
  • T Cabaleiro, M Román, JP Gisbert, F Abad-Santos. Utility of assesing thiopurine S-methyltransferase polymorphism before azathioprine therapy. Curr Drug Metab 2012; 13: 1277-1293.
  • D Serrano, S Torrado, S Torrado-Santiago, JP GisbertThe influence of CYP2C19 genetic polymorphism on the pharmacokinetics/pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments. Curr Drug Metab 2012; 13: 1303-1312.

  • M Gallach Montero, X Calvet, JP GisbertDispepsia no investigada. Blastonterología. Nº1, mayo 2011: 2-3.
  • J Amador, JP Gisbert, F Bermejo. Enfermedad Inflamatoria Intestinal. Clasificación, diagnóstico y tratamiento. Revista de la Sociedad Madrileña de Medicina de Familia y Comunitaria 2011; Nº 1 (Vol. 13): 42-52.
  • C López-Martín C, M Chaparro, L Espinosa, A Bejerano, J MatéJP GisbertAdverse events of thiopurine immunomodulators in patients with inflammatory bowel disease. Gastroenterol Hepatol 2011; 34:385-392.
  • J Legido, JP GisbertJ MatéAlteraciones del metabolismo óseo en 100 pacientes con enfermedad inflamatoria intestinal. Gastroenterol Hepatol 2011; 34: 379-384.
  • JI Fortea-Ormaechea, Y  González-Lama, B Casis, M Chaparro, P López Serrano, M Van Domselaar, F Bermejo, R Pajares, A Ponferrada, MI Vera, P Martinez Montiel, JP  Gisbert,  JL Pérez-Calle , A Lopez San Román, L Abreu, L Menchén, I Marín-Jiménez. Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn’s disease. The Madrid Experience. Gastroenterol Hepatol 2011; 34: 443-448.
  • A Barbero-Villares, J Mendoza-Jiménez, C Esteban, E Gómez-Domínguez, J MatéJP Gisbert, JA Moreno-Monteagudo, M García-Buey, R Gómez-Gil, T Sanz, E Daudén, R Moreno-Otero. Evaluation of liver fibrosis by transient elastography (Fibroscan) in methotrexate-treated patients. Med Clin (Barc) 2011; 137: 637-639.
  • I Marín, JP GisbertComentario sobre el artículo: Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn´s disease. Enfermedad Inflamatoria Intestinal al día 2011; Sección de Lectura Crítica de la Literatura. Vol. 10, nº 2: 141-144.
  • C Taxonera, JP GisbertComentario sobre el artículo: Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Enfermedad Inflamatoria Intestinal al día 2011. Sección de Lectura Crítica de la Literatura 2011; pags 210-214.
  • J Nuevo, M Tafalla, J Zapardiel, JP GisbertConsumo de recursos sanitarios y pérdida de productividad en la enfermedad por reflujo gastroesofágico: resultados de un estudio transversal en el ámbito de la atención primaria en España. Atención Primaria 2011; 43: 474-481.
  • S García, JP GisbertComentario sobre el artículo: FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease. Enfermedad Inflamatoria Intestinal al día 2011. Sección de Lectura Crítica de la Literatura 2011; pags 85-88.
  • E Domínguez-Muñoz, JP GisbertÚltimas novedades presentadas en gastroenterología. Introducción. Gastroenterol Hepatol 2011; 34 (Suppl.2): 1-2.
  • JP GisbertEnfermedades relacionadas con H. pylori: dispepsia, úlcera y cáncer gástrico. Gastroenterol Hepatol 2011. 34 (Suppl.2): 15-26.
  • M Barreiro, JP Gisbert. Comentario sobre el artículo: Infliximab, azathioprine, or combination therapy for Crohn’s disease. Enfermedad Inflamatoria Intestinal al día 2011; Sección de Lectura Crítica de la Literatura. Vol. 10, Nº 1: 77-81.
  • López-Martín C, De la Fuente-Fernández E, Corbatón P, Chaparro MGisbert JPHiperplasia nodular regenerativa: hepatotoxicidad por azatioprina en un paciente con enfermedad de Crohn. Gastroenterol Hepatol 2011; 34: 16-19.
  • JE Domínguez-Muñoz, JP GisbertÚltimas novedades presentadas en gastroenterología. Gastroenterol Hepatol 2011; 34 (Supl.1): 1-3.
  • JP GisbertEnfermedades relacionadas con H. pylori: dispepsia, úlcera y cáncer gástrico. Gastroenterol Hepatol 2011; 34 (Supl.1): 16-27.
  • JP GisbertTratamientos de rescate ante el fracaso erradicador de Helicobacter pylori. Gastroenterol Hepatol 2011; 34: 89-99.
  • MA Montoro, S Santolaria, B Sánchez Puértolas, J Vera, L Bujanda, A Cosme, JL Cabriada, M. Durán, L Mata, A Santamaría, G Ceña, JM Blas, J Ponce, M Ponce, L Rodrigo, J. Fernandez Sordo, C Muñoz, G. Arozena, D Ginard, A López-Serrano, M Castro, M Sans, R. Campo, A. Casalots, V Orive, A. Loizate, L Titó, E Portabella, P Otazua, M. Calvo, MT Botella, C Thomson, JL Mundi, E Quintero, D Nicolás, F Borda, B Martinez, JP GisbertM Chaparro, A Jimenez Bernadó, F Gómez-Camacho, A Cerezo, E. Casal Nuñez. On behalf of the Workgroup for the Study of Ischemic Colitis of the Spanish Gastroenterological Association (GTECIE-AEG). Clinical patterns, and outcomes of ischemic colitis: Results of the Working Group for the Study of Ischemic Colitis in Spain (CIE study). Scand J Gastroenterol 2011; 46: 236-246.
  • C. Taxonera, J. Estellés, I. Fernandez-Blanco, O. Merino, I. Marín-Jimenez, M. Barreiro, C. Saro, V. García, S. García-Morán, G. Bastida, JP. Gisbert, I. Vera, M. P. Martinez, Sara Garcia Morán,MD,María Chaparro,MD, J. L. Mendoza. Adalimumab induction and maintenance therapy for ulcerative colitis patients previously treated with Infliximab. Aliment Pharmacol Ther; 2011, 33: 340-348.
  • M Chaparro, J Panés, V García, M Mañosa, M Esteve, O Merino, JL Cabriada, MA Montoro, JL Mendoza, P Nos, A Gutierrez, F Gomollón, JP GisbertLong-term durability of infliximab treatment in Crohn’s disease and efficacy of dose “escalation” in patients loosing response. J Clin Gastroenterol 2011; 45:113-118.
  • A Lanas, LA Garcia Rodriguez, M Polo-Tomas, M Ponce, E. Quintero, A Pérez-Aisa, JP Gisbert, L Bujanda, M Castro, M Muñoz, D Del-Pino, S García, X Calvet. The changing face of hospitalization due to gastrointestinal bleeding and perforation. Aliment Pharmacol Ther 2011; 33: 585-591.
  • ID Pousa, A Algaba, PM Linares, P Sanz, J Maté, R Moreno-Otero, F Bermejo, JP GisbertCorticosteroids modulate angiogenic soluble factors in ulcerative colitis patients. Dig Dis Sci 2011; 56: 871-879.
  • JP GisbertM ChaparroM Esteve. Review article: Prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 619-633.
  • Malfertheiner P, Bazzoli F, Delchier JC, , Giguère MRivière MMégraud FPylera Study GroupCollaboratorsAisene A, Bougnol M, Cassigneul JCoulom PHoucke PLamarque DLamouliatte DRoques JFThevenin ADelchier JCEcuer SBagnouls GHelbert TAndree HBouzo HBrandt WCordes HJDettmer AJuergens HMalfertheiner PRehmann IRyschka ASchaefer TO’Morain CBazzoli FGasbarrini GCipolletta LStanghellini VKuipers EA de Boer WCeliñski KGachowski WHuk JJamrozik-Kruk ZKarnafel WKleczkowski DKujawski KLinke KPetryka RSerwin DWozniak BWysokinski ACastro MCalleja JLCalvet XGisbert JPMuñoz EDBundy COrpen IMohr DSParker ICahill THelicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377: 905-13.
  • J Sánchez-Delgado, E Gené, D Suarez, P García-Iglesias, E Brullet, M Gallach, F Feu, JP Gisbert, X Calvet. Has H. pylori prevalence in bleeding peptic ulcer been underestimated? A meta-regression. Am J Gastroenterol 2011; 106: 398-405.
  • M ChaparroJP GisbertSuccessful use of infliximab for perianal Crohn’s disease in pregnancy. Inflamm Bowel Dis 2011; 17: 868-869.
  • JF Rahier, P Papay, J Salleron, S Sebastian, M Marzo, L Peyrin-Biroulet, V Garcia-Sanchez, W Fries, DP van Asseldonk, K Farkas, NK de Boer, T Sipponen, P Ellul, E Louis, STC Peake, U Kopylov, J Maul, B Makhoul, G Fiorino, Y Yazdanpanah, M Chaparro, for the European Crohn’s and Colitis Organisation (ECCO). H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 2011; 60: 456-462.
  • N Nuñez, A Lamana, D Sancho, P Martín, JP Gisbert, F Sanchez-Madrid, A Urzainqui. P-Selectin Glycoprotein Ligand-1 modulates immune inflammatory responses in the enteric lamina propria. J Pathol 2011; 224: 212-221.
  • M ChaparroJP GisbertTransplacental transfer of immunosuppresants and biologics used for the treatment of inflammatory bowel disease. Current Pharmaceutical Biotechnology 2011; 12: 765-773.
  • J Panés, R Bouzas, M Chaparro, V García-Sánchez, JP Gisbert, B Martínez de Guereñu, JL Mendoza, JM Paredes, S Quiroga, T Ripollés, J Rimola. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther 2011; 34:125-145.
  • L Espinosa, P Muñoz, A Bejerano, C López, A Sánchez, R Moreno-Otero, JP GisbertSoluble angiogenic factors in patients with acute pancreatitis. J Clin Gastroenterol 2011; 45: 630-637.
  • P M LinaresJP GisbertRole of growth factors in the development of lymphangiogenesis driven by inflammatory bowel disease: a review. Inflamm Bowel Dis 2011; 17: 1814-1821.
  • I Guerra, M Chaparro, F Bermejo, JP GisbertUtility of Measuring anti-TNF agents and anti-drug antibodies serum concentrations in inflammatory bowel disease. Current Drug Metabolism 2011; 12: 594-598.
  • Y González-Lama, F Bermejo, A López-Sanromán, MV García, M Esteve, JL Cabriada, R Pajares R, F Casellas, O Merino, D Carpio, M Calvo, C Muñoz, M Calvo, LM Benito, L Bujanda, FJ García-Hernández, E Ricart, D Ginard, S Tabernero, M Velasco, JA Carneros, N Manceñido, MI Vera, AG McNicholl, A Algaba, C Froilan, L Abreu, J Maté, C Cara, JP Gisbert JP. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther 2011; 34: 544-554.
  • L Martín Martín, C Santander, MC López, J Espinoza-Rios, C Chavarría- Herbozo, R Moreno-Otero, JP GisbertOesophageal motor abnormalities in eosinophilic esophagitis identified by high resolution manometry. J Gastroenterol Hepatol 2011; 26: 1447-1450.
  • JP Gisbert, X Calvet. Review article: Non-bismuth quadruple (concomitant) therapy for Helicobater pylori eradication. Aliment Pharmacol Ther 2011; 34: 604-617.
  • F Gomollon, JP GisbertIntravenous iron in IBD—what’s the best preparation? Nature Reviews Gastroenterol & Hepatol 2011; 8: 477-478.
  • JP GisbertM Chaparro, F Gomollón. Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease. World J Gastroenterol 2011; 17: 3467-3478.
  • A O’Connor, JP Gisbert, D McNamara, CA O’Morain. The Year in Helicobacter. Treatment of Helicobacter pylori Infection. Helicobacter 2011; 16 (suppl.1): 53-58.
  • A Bortoli, N Pedersen, D Duricova, R D´Inca, P Gionchetti, MR Panelli, S Ardizzone,  A Lopez Sanroman, JP Gisbert, I Arena, G Riegler, A Kohn, D Valpiani,  A Corbellini, S Segato, F Castiglione,P Munkholm, on behalf of the European Crohn-Colitis Organisation study group. Pregnancy Outcome in Inflammatory Bowel Disease: Prospective European Case-control ECCO-EpiCom Study, 2003-2006. Aliment Pharmacol Ther 2011; 34: 724-734. Seleccionado por “Faculty of 1000 Medicine (www.f1000medicine.com)” como uno de los mejores artículos.
  • X Calvet, JP Gisbert, D Suarez. Key points for designing and reporting Helicobacter pylori therapeutic trials: A personal view. Helicobacter 2011; 16: 346-355.
  • Y González-Lama, JP GisbertAuthor reply: Thiopurine metabolite measurement −not for everyone. Aliment Pharmacol Ther 2011; 34: 1039-1040.
  • P García-Iglesias, A Villoria, D Suarez, E Brullet, M Gallach, F Feu, JP Gisbert,A Barkun, X Calvet. Meta-analysis: Predictors of rebleeding after endoscopic treatment for bleeding peptic ulcer. Aliment Pharmacol Ther 2011; 34: 888-900.
  • J Molina-Infante, JP GisbertLevofloxacin in first-line eradication regimens for Helicobacter pylori: better test antibiotic susceptibility before treating. Gut 2011; 60: 1605.
  • JP Gisbert, X Calvet. Review article: Common misconceptions in the management of H. pylori-associated gastric MALT-lymphoma. Aliment Pharmacol Ther 2011; 34: 1047-1062. Seleccionado como una de las publicaciones más relevantes en MDLinx.
  • Y González-Lama, JP GisbertThiopurine metabolites and TPMT activity measurement in inflammatory bowel disease: authors’ reply. Aliment Pharmacol Ther 2011; 34: 1139-1140.
  • B Hernández-Breijo, J Monserrat, S R. Rubio, E P. Cuevas, D Vara, I Díaz-Laviada, MD Fernández-Moreno, I D. Román, JP Gisbert, LG Guijarro. Preclinical evaluation of azathioprine plus buthionine sulfoximine in the treatment of human hepatocarcinoma and colon carcinoma. World J Gastroenterol 2011; 17: 3899-3911.
  • JP Gisbert, X Calvet. Review article: The effectiveness of standard triple-therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011; 34: 1255-1268.
  • JP GisbertIs culture necessary before first-line treatment for Helicobacter pylori infection? Internal Medicine 2011; 50: 2717.
  • J Ponce, X Calvet, M Gallach, M Ponce; Esophagitis Study Group of the Asociación Española de Gastroenterología (AEG). Esophagitis in a high H. pylori prevalence area: severe disease is rare but concomitant peptic ulcer is frequent. PLoS One. 2011;6(10):e25051

  • V García, JP GisbertComentario sobre el artículo: Infliximab prevents Crohn´s disease recurrence after ileal resection. Enfermedad Inflamatoria Intestinal al día 2010. Sección de Lectura Crítica de la Literatura; Vol. 9. Nº 1: 56-59.
  • F Gomollón, JP Gisbert¿Es necesario asociar inmunomoduladores al tratamiento biológico en la enfermedad inflamatoria intestinal? Gastroenterol Hepatol 2010; 33: 43-53.
  • M Chaparro, JP GisbertComentario sobre el artículo: Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Enfermedad Inflamatoria Intestinal al día 2010; Sección de Lectura Crítica de la Literatura. 2010; 9 (2):142-145.
  • F Gomollón, JP Gisbert¿Hasta cuándo mantener el tratamiento combinado de biológicos e inmunomoduladores en la enfermedad inflamatoria intestinal? Gastroenterol Hepatol 2010; 33: 472-473.
  • S García, JP GisbertComentario sobre el artículo: Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Enfermedad Inflamatoria Intestinal al día 2010; Sección de Lectura Crítica de la Literatura. Vol. 9, Nº 3: 202-205.
  • JP GisbertThe safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Proceedings of the “Miquel Angel Gassull” Course on Inflammatory Bowel Diseases, 2010; pag. 51-56.
  • M Tafalla, J Nuevo, J Zapardiel, JP GisbertEstudio de síntomas relevantes y atención clínica en la enfermedad por reflujo gastroesofágico en atención primaria en España. Gastroenterol Hepatol 2010; 33: 490-497.
  • F Mearin, A Balboa, A Castells, JE Domínguez, M Esteve, JA García-Erce, JP Gisbert, F Gomollón, J Panés, J Ponce. Anemia ferropénica y uso de hierro endovenoso en patología digestiva. Gastroenterol Hepatol 2010; 33: 605-613.
  • A Lanas, X Calvet, F Feu, J Ponce, JP Gisbert y A Barkun, en representación del Consenso sobre Hemorragia Digestiva por Úlcera Péptica. Primer Consenso Español sobre el tratamiento de la hemorragia digestiva por úlcera péptica. Med Clin (Barc) 2010; 135: 608-616.
  • JP Gisbert, F Gomollón. Tratamiento de la anemia en la enfermedad inflamatoria intestinal. Programa de Formación Continuada en Gastroenterología y Hepatología de la Asociación Española de Gastroenterología (AEG) y la Asociación Española para el Estudio del Hígado (AEEH). Gastroenterología y Hepatología Continuada. Ediciones Doyma, S.A., 2010; vol 9, nº 5: 238-242.
  • JP GisbertUtilidad de la determinación de la actividad de la tiopurina metiltransferasa (TPMT) para el ajuste de la dosis de azatioprina o mercaptopurina. Sección de Columnistas Expertos de Salud y Ciencia de la Sociedad Iberoamericana de Información Científica. Versión en Internet: www.siicsalud.com (http://www.siicsalud.com/dato/experto.php/112014).
  • I Galicia, F Abad Santos, JP GisbertEficacia de la levadura Saccharomyces boulardii como probiótico en el tratamiento de las enfermedades digestivas. Farmacoterapia 2010; 8: 165-176.
  • G González Alcaide, JM Ramos Rincón, JP GisbertColaboración científica y ámbitos de investigación en Gastroenterología y Hepatología. Revista Española de Enfermedades Digestivas (2000-2009). Gastroenterol Hepatol. 2010; 33: 670-680.
  • C Santander, JP Gisbert, R Moreno-Otero, AG McNichollJ MatéUsefulness of manometry to select patients wit anal fissure for controlled anal dilatation. Rev Esp Enferm Dig 2010; 102: 691-697.
  • R García de Vicuña, B Padilla, L Carreño, S Muñoz Fernández, E Martín Mola, J Gómez-Reino, V Martínez Taboada, A López Sanromán, JP Gisbert, F Díaz González, J Hinojosa Del Val, E Bouza, L Carmona. Recomendaciones de manejo de la gripeA (H1N1) en pacientes reumáticos con inmunosupresión. Reumatol Clin 2010; 6: 63-8.
  • JP GisbertDiez noticias relevantes para la práctica clínica en Gastroenterología publicadas en el año 2010. Gastroenterol Hepatol 2011; 34: 289-304.
  • JP Gisbert, A Cooper, D Karagiannis, J Hatlebakk, L Agréus, H Jablonowski, M Tafalla. Consultation rates and characteristics of gastroesophageal reflux disease in primary care: A European observational study 2009; Eur J Gen Pract; 15: 154-160.
  • F Bermejo, A Lopez-SanRoman, A Algaba, M Van-Domselaar, JP Gisbert, E Garrido, S García-Garzón, G de la Poza, B Piqueras. Mercaptopurine rescue after azathioprine-induced liver injury in inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31: 120-124.
  • ME Fernández-Contreras, JJ Sánchez-Hernández, M Guijarro, JP Gisbert, ML García de Paredes, C Gamallo. Influence of thymidylate synthase (TS) DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer. Oncology Reports. Oncol Rep 2010; 23:1393-400.
  • JP Gisbert, A Pérez-Aisa, M Castro-Fernández, J. Barrio, L. Rodrigo, A. Cosme, J.L. Gisbert, S Marcos. Helicobacter pylori first-line treatment and levofloxacin-based rescue option in patients allergic to penicillin. Dig Liver Dis 2010; 42: 287-290.
  • JP GisbertThe safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis. 2010;16:881-95.
  • JP Gisbert, X Calvet, JPA O’Connor, F Mégraud, CA O’Morain. Sequential therapy for Helicobater pylori eradication: a critical review. J Clin Gastroenterol. 2010;44:313-25.
  • J Panés, JP GisbertOptimizing care of Hereditary Hemorrhagic Telangiectasia. Gastroenterology. Gastroenterology 2010; 138: 2014-2016.
  • JP Gisbert, X Calvet, JPA O’Connor, F Mégraud, CA O’Morain. The sequential therapy regimen for Helicobacter pylori eradication. Expert Opin Pharmacother. 2010 11:905-18.
  • J Molina-Infante, M Fernandez-Bermejo, B Perez-Gallardo, M Hernandez-Alonso, JM Mateos, C Dueñas, EG Abadia, GG Garcia, JP GisbertClinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010; 31: 1077-1084.
  • V García Sánchez, E Iglesias Flores, R González Ojeda, JP Gisbert, L Castillo Molina, L Vida Pérez, JM Gallardo Valverde, A González Galilea, A Naranjo Rodríguez, JF de Dios Vega, J Muntané Relat, F Gómez Camacho. Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? J Crohn Colitis 2010; 4: 144-152.
  • J Molina-Infante, JP GisbertClarithromycin or levofloxacin in the sequential therapy for H. pylori? Aliment Pharmacol Ther 2010; 31: 1249-1250.
  • F Gomollón, JP GisbertIntravenous iron in digestive diseases: a clinical (re)view. Therapeutic Advances in Chronic Disease 2010; 1: 67-75.
  • J Molina-Infante, JP GisbertReply to letter by Wong and Tan: One size does not fit all – time to regionalize Helicobacter pylori eradication? Aliment Pharmacol Ther 2010; 32: 507-508.
  • F Bermejo, JP GisbertUsefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies. Therapeutic Advances in Chronic Disease 2010; 1: 107-114.
  • C Teruel, A López-San Román, C Taxonera, A Algaba, JP Gisbert, JL Perez-Calle, M Martín-Arranz, M Van Domselaar, J Estellés, F Bermejo, PM Linares, P Lopez. Outcomes in pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines. Am J Gastroenterol 2010; 105: 2003-2008.
  • M Chaparro, A Barbero, L Martín, C Esteban, L Espinosa, F de la Morena, A Sánchez, I Martín, C Santander, R Moreno-Otero, JP GisbertProspective evaluation of a clinical guideline recommending early patients discharge in bleeding peptic upper. J Gastroenterol Hepatol 2010; 25: 1525-1529.
  • JP Gisbert, JM Pajares. Treatment of Helicobacter pylori infection: the past and the future. Eur J Intern Med 2010; 21: 357-359.
  • V García Sánchez, R González Ojeda, E Iglesias Flores, JP Gisbert, JM Ángel Rey, C Llamoza Torres, JM Gallardo Valverde, A Reyes López, C Gálvez Calderón, JF de Dios Vega, J Muntané Relat, F Gómez Camacho. Can systemic cytokines predict relapse of inflammatory bowel disease? Hepatogastroenterology 2010; 57: 524-530.
  • C Loras, JP Gisbert, M Mínguez, O Merino, L Bujanda, C Saro, E Domenech, J Barrio, M Andreu, I Ordás, L Vida, G Bastida, F González-Huix, M Piqueras, D Ginard, X Calvet, A Gutiérrez, A Abad, M Torres, J Panés, M Chaparro, I Pascual, M Rodriguez-Carballeira, F Fernández-Bañares, JM Viver, M Esteve; for the REPENTINA study; GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa) Group. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010; 59: 1340-1346. Merecedor de un Editorial en el mismo número de la revista, titulado: “Liver disfunction in patients with IBD under immunusuppressive treatment: do we need to fear?”
  • A O’Connor, JP Gisbert, D McNamara, CA O’Morain. The Year in Helicobacter. Treatment of Helicobacter pylori. Infection 2010; 15 (Suppl.1): 46-52.
  • JP GisbertSequential or concomitant therapy for Helicobacter pylori eradication? J Clin Gastroenterol 2010; 44: 658-659.
  • C Rubio-Terrés, A Fernández López, A Fernández Montero, JM López Vega, A Martínez Castelao, JP Gisbert, M Quirós Valera, JP Ordovás Baines. Análisis farmacoeconómico del tratamiento de la deficiencia de hierro carboximaltosa (Ferinject®) en España. Pharmacoeconomics 2010; 7: 109-117.
  • JP Gisbert, F Gomollón, J Hinojosa, AL López San Román. Adherence of gastroenterologists to European Crohn’s and Colitis Organisation Consensus on ulcerative colitis: a real-life survey in Spain. J Crohn’s Colitis 2010; 4: 567-574.